Loading..

Amgen Inc. (AMGN) Report Analysis

Corporate Events

Neutral

Amgen Inc. Presents at 5th LSX USA Congress & C...

2022-06-16 19:39:00

Amgen Inc. Presents at 5th LSX USA Congress & CEO Forums, Jun-21-2022 . Venue: Boston, United States.

Neutral

Amgen Inc. Reaffirms Revenue Guidance for the Year 2022

2022-06-15 17:40:00

Amgen Inc. reaffirmed revenue guidance for the year 2022. The company reaffirmed going to 2022 revenue ranges despite by headwinds.

Neutral

Amgen Inc. Presents at Goldman Sachs 43rd Annua...

2022-06-10 20:15:00

Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 10:40 AM. Venue: Terranea Resort, Rancho Palos Verd...

Neutral

Amgen Inc. Presents at Antibody Engineering & T...

2022-06-06 15:28:00

Amgen Inc. Presents at Antibody Engineering & Therapeutics Europe, Jun-09-2022 03:25 PM. Venue: Amsterdam, Netherlands. Speakers: Brian Avanzi...

Positive

Amgen Inc. Announces U.S. Food and Drug Adminis...

2022-06-06 13:00:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combinati...

Positive

Amgen and Takeda Pharmaceutical Company Announc...

2022-06-05 12:00:00

Amgen and Takeda Pharmaceutical Company announced that new data from the Phase 3 PARADIGM clinical trial of Vectibix® (panitumumab) in Japanes...

Neutral

Amgen Inc. Presents at 2022 Jefferies Global He...

2022-06-03 20:00:00

Amgen Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 09:30 AM. Venue: Marriott Marquis, New York City, New York, Un...

Neutral

I.I.R Ltd., Antibody Engineering & Therapeutics...

2022-06-01 12:03:00

I.I.R Ltd., Antibody Engineering & Therapeutics Europe, Jun 07, 2022 through Jun 09, 2022. Venue: Amsterdam, Netherlands.

Positive

Amgen Announces Positive Topline Phase 2 Data f...

2022-05-31 13:00:00

Amgen announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult pati...

Neutral

Amgen Inc. Presents at DIA Global Annual Meetin...

2022-05-28 18:13:00

Amgen Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022 . Venue: Chicago, Illinois, United States. Speakers: Cathy Critchlow, Vice ...

Neutral

Amgen Inc. Presents at The 2022 ASCO Annual Mee...

2022-05-26 21:00:00

Amgen Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022. Venue: McCormick Place, Chicago, Illinois, United States...

Neutral

Amgen Inc. Presents at CHCI Issue Summits, May-17-2022

2022-05-16 18:03:00

Amgen Inc. Presents at CHCI Issue Summits, May-17-2022 . Venue: 600 14th Street NW, Washington, District Of Columbia, United States. Speakers:...

Neutral

Amgen Inc. Presents at BIO International Conven...

2022-05-15 00:00:00

Amgen Inc. Presents at BIO International Convention 2022, Jun-13-2022 . Venue: San Diego Convention Center, San Diego, California, United Stat...

Neutral

Amgen Inc. Presents at Preclinical Immuno-Oncol...

2022-05-13 02:43:00

Amgen Inc. Presents at Preclinical Immuno-Oncology: Online Seminar, May-18-2022. Presentation Date & Speakers: May-18-2022, Deepali Sawant, Pr...

Neutral

Amgen Inc. Presents at American Association of ...

2022-05-12 18:39:00

Amgen Inc. Presents at American Association of Clinical Endocrinology (AACE) Annual Meeting, May-12-2022 . Venue: San Diego, United States. Sp...

Neutral

Congressional Hispanic Caucus Institute, CHCI I...

2022-05-10 19:40:00

Congressional Hispanic Caucus Institute, CHCI Issue Summits, May 17, 2022 through May 18, 2022. Venue: 600 14th Street NW, Washington, Distric...

Neutral

patientNOW, Inc, Rx Marketing Group, 17th Editi...

2022-05-05 12:30:00

patientNOW, Inc, Rx Marketing Group, 17th Edition of the Music City Symposium for Cosmetic Advances & Laser Education, May 11, 2022 through M...

Neutral

Tranche Update on Amgen Inc. (NasdaqGS:AMGN)'s ...

2022-04-28 10:19:00

From January 1, 2022 to March 31, 2022, the company has repurchased 24,622,497 shares, representing 4.41% for $6,310.11 million. With this, th...

Neutral

Amgen Inc. Provides Earnings Guidance for the Year 2022

2022-04-27 20:20:00

Amgen Inc. provided earnings guidance for the year 2022. For the year, the company expects total revenues in the range of $25.4 billion to $26...

Positive

Amgen Announces Top-Line Results from Two Repat...

2022-04-27 13:00:00

Amgen announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER cardiovascular outco...

Neutral

Amgen Inc. Presents at PEGS Boston Conference 2...

2022-04-23 07:37:00

Amgen Inc. Presents at PEGS Boston Conference 2022, May-04-2022 09:00 AM. Venue: Boston, Massachusetts, United States. Speakers: Katherine Har...

Neutral

Amgen Inc. to Report Q1, 2022 Results on Apr 27, 2022

2022-04-22 20:00:00

Amgen Inc. announced that they will report Q1, 2022 results After-Market on Apr 27, 2022

Neutral

Amgen Inc. Presents at 2022 Fc Receptor and IgG...

2022-04-21 15:29:00

Amgen Inc. Presents at 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr-26-2022 . Venue: Boston, Massachusetts, United States. Spea...

Neutral

Hanson Wade Limited, 2022 Fc Receptor and IgG T...

2022-04-21 09:39:00

Hanson Wade Limited, 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr 26, 2022 through Apr 28, 2022. Venue: Boston, Massachusetts, ...

Positive

Amgen Announces Positive Top-Line Results from ...

2022-04-18 20:00:00

Amgen announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA® (ustekinumab) in a...

Neutral

Amgen Inc. Presents at Drug Discovery Chemistry...

2022-04-14 17:07:00

Amgen Inc. Presents at Drug Discovery Chemistry Conference 2022, Apr-18-2022 through Apr-21-2022. Presentation Date & Speakers: Apr-18-2022, R...

Neutral

Cambridge Innovation Institute, LLC, Drug Disco...

2022-04-14 12:01:00

Cambridge Innovation Institute, LLC, Drug Discovery Chemistry Conference 2022, Apr 18, 2022 through Apr 21, 2022.

Neutral

Amgen Inc., Q1 2022 Earnings Call, Apr 27, 2022

2022-04-13 00:00:00

Amgen Inc., Q1 2022 Earnings Call, Apr 27, 2022

Positive

Amgen Inc. Announces the Presentation of Long-T...

2022-04-10 16:00:00

Amgen announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutat...

Neutral

Amgen Inc., Annual General Meeting, May 17, 2022

2022-04-05 20:11:00

Amgen Inc., Annual General Meeting, May 17, 2022, at 11:00 Pacific Standard Time. Agenda: To elect twelve directors to the Board of Directors ...

Neutral

Amgen Inc. - Shareholder/Analyst Call

2022-04-05 20:11:00

AGM

Neutral

Amgen Inc. Presents at Pharma Manufacturing Wor...

2022-03-29 08:36:00

Amgen Inc. Presents at Pharma Manufacturing World Summit, Mar-29-2022 . Venue: Boston Marriott Copley Place, Boston, Massachusetts, United Sta...

Neutral

Amgen Inc. Presents at Bank of America 2022 Hea...

2022-03-22 05:03:00

Amgen Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 09:20 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vega...

Neutral

Executive Platforms Inc., Pharma Manufacturing ...

2022-03-21 14:57:00

Executive Platforms Inc., Pharma Manufacturing World Summit, Mar 29, 2022 through Mar 30, 2022. Venue: Boston Marriott Copley Place, Boston, M...

Neutral

Amgen Inc. Presents at AACR Annual Meeting 2022...

2022-03-08 21:30:00

Amgen Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022. Venue: Ernest N. Morial Convention Center, New Orleans, Loui...

Positive

Amgen Inc., $ 1.94, Cash Dividend, May-16-2022

2022-03-02 00:00:00

Amgen Inc., $ 1.94, Cash Dividend, May-16-2022

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

Oxford Global Marketing Ltd., Preclinical Immun...

2022-02-16 04:05:00

Oxford Global Marketing Ltd., Preclinical Immuno-Oncology: Online Seminar, May 18, 2022.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Amgen Inc. Provides Earnings Guidance for 2022

2022-02-08 13:00:00

Amgen Inc. provides earnings guidance for 2022. For 2022, the company is expecting revenue of $25.4 billion to $26.5 billion, an EPS of $17 to $18.

Neutral

Amgen Inc. Presents at 2022 OBIO Investment Sum...

2022-02-08 08:05:00

Amgen Inc. Presents at 2022 OBIO Investment Summit, Feb-09-2022 12:00 PM. Speakers: Angela Behboodi, Philip Tagari.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Neutral

Amgen Inc. Presents at SCOPE Summit 2022, Feb-0...

2022-02-04 08:35:00

Amgen Inc. Presents at SCOPE Summit 2022, Feb-09-2022 11:25 AM. Venue: Orlanda, Florida, United States. Speakers: Michael Morozewicz, Senior M...

Positive

Amgen Inc. and Plexium Inc. Announces Multi-Yea...

2022-02-03 14:00:00

Amgen Inc. and Plexium, Inc. announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targ...

Neutral

Ontario Bioscience Innovation Organization, 202...

2022-01-26 12:49:00

Ontario Bioscience Innovation Organization, 2022 OBIO Investment Summit, Feb 09, 2022 through Feb 11, 2022.

Neutral

Amgen Inc. to Report Q4, 2021 Results on Feb 07, 2022

2022-01-26 02:31:00

Amgen Inc. announced that they will report Q4, 2021 results at 4:00 PM, Eastern Standard Time on Feb 07, 2022

Neutral

Amgen Inc. - Special Call

2022-01-26 02:31:00

To review the company's strategy, operations, pipeline, research capabilities and growth outlook

Neutral

American Association For Cancer Research, AACR ...

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Cent...

Neutral

Cambridge Innovation Institute, LLC, PEGS Bosto...

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Mass General Brigham Incorporated, World Medica...

2022-01-06 16:02:00

Mass General Brigham Incorporated, World Medical Innovation Forum, May 02, 2022 through May 04, 2022. Venue: Westin Copley, Boston, Massachuse...

Neutral

Amgen Inc. Presents at World Medical Innovation...

2022-01-06 16:02:00

Amgen Inc. Presents at World Medical Innovation Forum, May-02-2022 . Venue: Westin Copley, Boston, Massachusetts, United States. Speakers: Rob...

Positive

Amgen Announces FDA Approves Otezla® (Apremilast)

2021-12-20 21:25:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult patients with pl...

Positive

Amgen Announces That the U.S. Food and Drug Adm...

2021-12-17 21:30:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™ (tezepelumab-ekko) for the add...

Positive

Syngene International Limited Announces Extensi...

2021-12-16 06:07:00

Syngene International Limited announced the extension of its long-standing multi-discipline research collaboration with Amgen Inc. The contrac...

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Neutral

Drug Information Association, Inc., DIA Global ...

2021-12-10 06:32:00

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022. Venue: Chicago, Illinois, United States.

Neutral

Amgen Inc. Presents at BioFlorida Conference, D...

2021-12-07 04:14:00

Amgen Inc. Presents at BioFlorida Conference, Dec-09-2021 11:15 AM. Venue: Renaissance Orlando at SeaWorld, 6677 Sea Harbor Dr, Orlando, Flori...

Positive

Amgen Announces New Data Being Presented At ASH 2021

2021-12-06 21:00:00

Amgen announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rdAmerican Society of Hematology (ASH) A...

Positive

Amgen Declares 2022 First Quarter Dividend, Pay...

2021-12-03 21:00:00

Amgen announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will be paid on Ma...

Positive

Amgen Inc., $ 1.94, Cash Dividend, Feb-14-2022

2021-12-03 00:00:00

Amgen Inc., $ 1.94, Cash Dividend, Feb-14-2022

Positive

Amgen Inc. Announces Positive Top-Line Results ...

2021-12-01 21:00:00

Amgen Inc. announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind s...

Positive

FDA Approves New KYPROLIS® (carfilzomib) Combin...

2021-12-01 18:28:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS® (carfilzomib) U.S. prescribing in...

Neutral

Amgen Inc. Presents at 4th Annual Evercore ISI ...

2021-11-24 21:05:00

Amgen Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 05:10 PM. Speakers: Rob Lenz, Senior Vice President ...

Neutral

Amgen Inc. Presents at Piper Sandler 33rd Annua...

2021-11-22 15:06:00

Amgen Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Dec-01-2021 01:00 PM. Venue: New York, New York, United States...

Positive

Amgen Announces the Committee for Medicinal Pro...

2021-11-12 12:30:00

Amgen announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion re...

Neutral

FRISQ Holding AB (publ) in Collaboration with U...

2021-11-11 10:15:00

FRISQ Holding AB (publ) has entered into an agreement with biotechnology companies UCB and Amgen, to collaborate with selected clinics to desi...

Neutral

Amgen Inc. Presents at Cowen’s 5th Annual IO Ne...

2021-11-10 21:00:00

Amgen Inc. Presents at Cowen’s 5th Annual IO Next Virtual Summit, Nov-15-2021 02:15 PM. Speakers: David M. Reese, Executive Vice President of ...

Neutral

Biotechnology Innovation Organization, BIO Inte...

2021-11-09 17:12:00

Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022. Venue: San Diego Convention Cente...

Neutral

Biotechnology Innovation Organization, BIO Inte...

2021-11-09 17:12:00

Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022. Venue: San Diego Convention Cente...

Positive

Amgen Announces New Data from the HER-MES Study

2021-11-08 21:09:00

Amgen announced new data from the HER-MES study, the first and only head-to-head study of Aimovig® (erenumab-aooe), a calcitonin gene-related ...

Neutral

Amgen Inc. Presents at 30th Annual Credit Suiss...

2021-11-07 10:00:00

Amgen Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-10-2021 . Venue: Rancho Palos Verdes, California, United States. S...

Positive

Amgen Inc. Begins Construction on New Biomanufa...

2021-11-05 20:00:00

Amgen Inc. announced the groundbreaking of its newest biomanufacturing plant, located in New Albany, Ohio. The final product assembly and pack...

Neutral

Amgen Inc. Presents at BMO Biopharma Spotlight ...

2021-11-04 13:52:00

Amgen Inc. Presents at BMO Biopharma Spotlight Series: Emerging Trends & Therapeutics in Oncology, Nov-08-2021 02:05 PM. Speakers: David M. Re...

Neutral

Amgen Inc. has filed a Shelf Registration in th...

2021-11-03 00:00:00

Amgen Inc. has filed a Shelf Registration in the amount of $42.852 million. Security Name: Common Stock Securities Offered: 200,000 Trans...

Neutral

Amgen Inc. Provides Earnings Guidance for the Year 2021

2021-11-02 20:01:00

Amgen Inc. provided earnings guidance for the year 2021. For the full year 2021, the Company now expects: total revenues in the range of $25.8...

Neutral

Tranche Update on Amgen Inc. (NasdaqGS:AMGN)'s ...

2021-11-02 16:28:00

From July 1, 2021 to September 30, 2021, the company has repurchased 4,638,964 shares, representing 0.81% for $1,068.96 million. With this, th...

Neutral

BMO Capital Markets Corp., BMO Biopharma Spotli...

2021-11-01 12:00:00

BMO Capital Markets Corp., BMO Biopharma Spotlight Series: Emerging Trends & Therapeutics in Oncology, Nov 08, 2021.

Neutral

Amgen Inc. to Report Q3, 2021 Results on Nov 02, 2021

2021-10-28 20:00:00

Amgen Inc. announced that they will report Q3, 2021 results After-Market on Nov 02, 2021

Neutral

Informa plc, Competition Law in the Pharmaceuti...

2021-10-27 16:16:00

Informa plc, Competition Law in the Pharmaceutical Sector programme, Nov 05, 2021.

Neutral

Amgen Inc. Presents at Competition Law in the P...

2021-10-27 16:16:00

Amgen Inc. Presents at Competition Law in the Pharmaceutical Sector programme, Nov-05-2021 .

Neutral

Amgen Inc. Presents at BioData World Congress 2...

2021-10-26 19:08:00

Amgen Inc. Presents at BioData World Congress 2021, Nov-02-2021 through Nov-04-2021. Presentation Date & Speakers: Nov-02-2021, Adrien Rousset...

Neutral

Cowen and Company, LLC, Cowen’s 5th Annual IO N...

2021-10-25 20:58:00

Cowen and Company, LLC, Cowen’s 5th Annual IO Next Virtual Summit, Nov 15, 2021.

Positive

Amgen Inc. Declares Dividend for the Fourth Qua...

2021-10-21 20:00:00

Amgen Inc. announced that its Board of Directors declared a $1.76 per share dividend for the fourth quarter of 2021. The dividend will be paid...

Positive

Amgen Inc., $ 1.76, Cash Dividend, Nov-15-2021

2021-10-21 00:00:00

Amgen Inc., $ 1.76, Cash Dividend, Nov-15-2021

Neutral

Amgen Inc. Presents at 4th Annual Targeted Prot...

2021-10-19 20:56:00

Amgen Inc. Presents at 4th Annual Targeted Protein Degradation Summit, Oct-27-2021 02:15 PM. Speakers: Ryan Potts, Head of Induced Proximity Platform.

Positive

Amgen Inc. (NasdaqGS:AMGN) completed the acquis...

2021-10-19 00:00:00

Amgen Inc. (NasdaqGS:AMGN) announced an agreement to acquire TeneoBio, Inc. from Lightspeed Venture Partners, Sutter Hill Ventures and others ...

Neutral

Jasper Therapeutics, Inc. has filed a Shelf Reg...

2021-10-15 00:00:00

Jasper Therapeutics, Inc. has filed a Shelf Registration in the amount of $277.553726 million. Security Name: Common Stock Securities Offe...

Neutral

Hanson Wade Limited, 4th Annual Targeted Protei...

2021-10-13 11:00:00

Hanson Wade Limited, 4th Annual Targeted Protein Degradation Summit, Oct 26, 2021 through Oct 29, 2021.

Neutral

Amgen Inc., Q3 2021 Earnings Call, Nov 02, 2021

2021-10-13 06:54:00

Amgen Inc., Q3 2021 Earnings Call, Nov 02, 2021

Positive

Amgen Announces New LUMAKRAS™ (sotorasib) Combi...

2021-10-07 13:00:00

Amgen announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating t...

Positive

Amgen and Neumora Therapeutics Announce Strateg...

2021-10-07 10:30:00

Amgen Inc. and Neumora Therapeutics Inc. announced a strategic collaboration to advance neuroscience discovery, development and commercializat...

Positive

Neumora announced that it has received $500 mil...

2021-10-07 00:00:00

Neumora announced that it has received $500 million in a round of funding led by Arch Venture Partners, L.P. on October 7, 2021. The company i...

Neutral

Amgen Inc. Presents at DIA: Digital Technology ...

2021-10-06 16:45:00

Amgen Inc. Presents at DIA: Digital Technology in Clinical Trials conference, Oct-27-2021 . Speakers: Alison Luckman, Development Operations I...

Neutral

Drug Information Association, Inc., DIA: Digita...

2021-10-06 12:29:00

Drug Information Association, Inc., DIA: Digital Technology in Clinical Trials conference, Oct 27, 2021 through Oct 29, 2021.

Neutral

Terrapinn Holdings Ltd, BioData World Congress ...

2021-10-06 12:29:00

Terrapinn Holdings Ltd, BioData World Congress 2021, Nov 02, 2021 through Nov 04, 2021.

Neutral

Amgen Inc. Presents at AusBiotech 2021, Oct-27-...

2021-10-05 13:01:00

Amgen Inc. Presents at AusBiotech 2021, Oct-27-2021 01:30 PM. Speakers: Amanda Mason, Global Head of Search and Evaluation for Inflammation/Im...

Neutral

AusBiotech Ltd., AusBiotech 2021, Oct 25, 2021 ...

2021-10-05 08:37:00

AusBiotech Ltd., AusBiotech 2021, Oct 25, 2021 through Oct 29, 2021.

Positive

Kyowa Kirin and Amgen Present Positive Late-Bre...

2021-10-02 09:00:00

Kyowa Kirin Co., Ltd. and Amgen announced that positive data from a Phase 2 study of KHK4083/AMG 451 were presented at the European Academy of...

Neutral

BioFlorida, Inc., Brain Foundation, BioFlorida ...

2021-10-01 16:14:00

BioFlorida, Inc., Brain Foundation, BioFlorida Conference, Dec 08, 2021 through Dec 10, 2021. Venue: Renaissance Orlando at SeaWorld, 6677 Sea...

Positive

Amgen Inc. announces an Increase in Equity Buyback.

2021-10-01 00:00:00

In October 2021, the company announced an increase in its equity buyback plan. The company increased its authorization by $4,500 million, ther...

Neutral

Amgen Inc. Presents at 30th European Academy of...

2021-09-29 10:50:00

Amgen Inc. Presents at 30th European Academy of Dermatology and Venereology Congress, Sep-29-2021 .

Neutral

Amgen Inc. Presents at HealthTech Innovation Da...

2021-09-29 07:24:00

Amgen Inc. Presents at HealthTech Innovation Days 2021, Oct-05-2021 04:50 PM. Venue: Paris, France. Speakers: Isma Benattia, VP R&D Strategy &...

Neutral

Amgen Inc. Presents at Longwood Healthcare Lead...

2021-09-28 18:44:00

Amgen Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 through Oct-05-2021. Presentation Date & Speakers: Oct-04-2021, Ray...

Neutral

Longwood Fund, Longwood Healthcare Leaders Conf...

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Neutral

Amgen Inc. Presents at Heartland Summit, Sep-30...

2021-09-27 03:33:00

Amgen Inc. Presents at Heartland Summit, Sep-30-2021 08:00 AM. Venue: Minnepolis, Minnesota, United States. Speakers: Robert A. Bradway, Chair...

Positive

Amgen Announces U.S. Food and Drug Administrati...

2021-09-25 00:09:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and other low-densit...

Positive

Amplitude Healthcare Acquisition Corporation an...

2021-09-24 00:00:00

On September 24, 2021, Jasper Therapeutics, Inc. closed the transaction.

Neutral

Amgen Inc. Presents at Cantor Global Healthcare...

2021-09-22 20:00:00

Amgen Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 02:00 PM. Venue: New York, United States. Speakers: Peter H. Grif...

Neutral

Amgen Inc. Presents at Festival of Biologics Ba...

2021-09-22 15:38:00

Amgen Inc. Presents at Festival of Biologics Basel 2021, Nov-10-2021 03:00 PM. Venue: Congress Centre, Basel, Switzerland. Speakers: María Luc...

Neutral

Amgen Inc. Presents at Ninth Annual C-Suite Sum...

2021-09-21 13:00:00

Amgen Inc. Presents at Ninth Annual C-Suite Summit, Oct-15-2021 . Speakers: Elliott Levy, Head, Intrepid Alliance.

Neutral

European Academy Of Dermatology And Venereology...

2021-09-20 12:00:00

European Academy Of Dermatology And Venereology, 30th European Academy of Dermatology and Venereology Congress, Sep 29, 2021 through Oct 02, 2021.

Positive

Verastem Oncology and Amgen Partner to Evaluate...

2021-09-20 11:00:00

Verastem Oncology announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766, Verastem Oncology’s investig...

Neutral

Amgen Inc. Presents at Indegene Digital Summit,...

2021-09-16 17:31:00

Amgen Inc. Presents at Indegene Digital Summit, Sep-24-2021 09:30 AM. Speakers: Nerissa Gomes, Director, Marketing & Lifecycle Management (Inf...

Neutral

Amgen Inc. Presents at 3rd Annual RAS Targeted ...

2021-09-16 13:29:00

Amgen Inc. Presents at 3rd Annual RAS Targeted Drug Development Summit, Sep-21-2021 through Sep-23-2021. Presentation Date & Speakers: Sep-22-...

Positive

Amgen Inc. Announces the First Combination Stud...

2021-09-16 08:30:00

Amgen Inc. announced the first combination study results from the Phase 1b/2 CodeBreaK 101 study, the most comprehensive global clinical devel...

Neutral

Indegene, Inc., Indegene Digital Summit, Sep 23...

2021-09-15 12:30:00

Indegene, Inc., Indegene Digital Summit, Sep 23, 2021 through Sep 24, 2021.

Positive

Health Canada Approves Amgen's LUMAKRAS™ (Sotor...

2021-09-14 11:00:00

Amgen announced that Health Canada has approved LUMAKRASTM (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally adva...

Neutral

Amgen Inc. Presents at Bank of America Global H...

2021-09-13 20:15:00

Amgen Inc. Presents at Bank of America Global Healthcare Conference, Sep-17-2021 11:45 AM. Speakers: Peter H. Griffith, Executive VP & CFO.

Neutral

Amgen Inc. - Special Call

2021-09-13 20:03:00

To discuss clinical data being presented on the Company's KRASG12C inhibitor LUMAKRAS(TM) (sotorasib) in combination with Vectibix(R) (panitumumab)

Neutral

Amgen Inc. - Special Call

2021-09-13 13:00:00

To discuss clinical data being presented at EADV, including data from the AMG 451/KHK4083 Phase 2 trial in patients with moderate-to-severe at...

Neutral

EIT Health e.V., HealthTech Innovation Days 202...

2021-09-13 06:00:00

EIT Health e.V., HealthTech Innovation Days 2021, Oct 04, 2021 through Oct 05, 2021. Venue: Paris, France.

Neutral

Amgen Inc. Presents at Morgan Stanley 19th Annu...

2021-09-09 21:00:00

Amgen Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 02:45 PM. Venue: New Windsor, United States. Speak...

Positive

Amgen Announces Results from Two Analyses of th...

2021-09-08 20:00:00

Amgen announced results from two analyses of the Phase 2 CodeBreaK 100 clinical trial evaluating LUMAKRAS™ (sotorasib), the first and only KRA...

Positive

Amgen Announces New Data from the Pivotal Navig...

2021-09-05 11:15:00

Amgen announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung funct...

Neutral

Cambridge Innovation Institute, LLC, SCOPE Summ...

2021-09-04 12:00:00

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022. Venue: Orlanda, Florida, United States.

Neutral

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun...

2021-09-04 07:34:00

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun 21, 2022 through Jun 22, 2022. Venue: Boston, United States.

Neutral

I.I.R Ltd., Competition Law in the Pharmaceutic...

2021-09-03 12:40:00

I.I.R Ltd., Competition Law in the Pharmaceutical Sector Conference, Dec 02, 2021. Venue: Le Châtelain Boutique Hôtel, Brussels, Belgium.

Neutral

Amgen Inc. Presents at Competition Law in the P...

2021-09-03 12:40:00

Amgen Inc. Presents at Competition Law in the Pharmaceutical Sector Conference, Dec-02-2021 11:05 AM. Venue: Le Châtelain Boutique Hôtel, Brus...

Neutral

Amgen Inc. Presents at Citi’s 16th Annual BioPh...

2021-09-01 18:36:00

Amgen Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 01:25 PM. Venue: New York, United States. Speakers: Murdo ...

Positive

Amgen Inc. Announces New Data at ESC Congress 2...

2021-08-27 08:30:00

Amgen announced positive data from the HUYGENS Phase 3 study showing that Repatha (evolocumab) in addition to optimized statin therapy, in com...

Neutral

Amgen Inc. Presents at 6th Annual CAR-TCR Summi...

2021-08-27 01:42:00

Amgen Inc. Presents at 6th Annual CAR-TCR Summit, Aug-30-2021 09:30 AM. Venue: Hynes Convention Center, Boston, Massachusetts, United States. ...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Amgen Inc. Presents at European Society for Med...

2021-08-23 12:06:00

Amgen Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 . Venue: Paris Expo Porte de Versailles, Paris...

Neutral

Amgen Inc. Presents at World Vaccine & Immunoth...

2021-08-18 15:33:00

Amgen Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 through Dec-02-2021. Venue: Loews Coronado Bay Reso...

Positive

Amgen Inc. Issues and Sale $1,250,000,000 Aggre...

2021-08-09 20:07:00

On August 9, 2021, Amgen Inc. issued and sold $1,250,000,000 aggregate principal amount of its 1.650% Senior Notes due 2028 (the “2028 Notes”)...

Neutral

Amgen Inc. Presents at MD&M West conference, Au...

2021-08-07 01:49:00

Amgen Inc. Presents at MD&M West conference, Aug-10-2021 . Venue: Anaheim Convention Cente, Anahiem, California, United States. Speakers: Bano...

Neutral

Amgen Inc. Presents at ATX West 2021, Aug-10-2021

2021-08-07 01:17:00

Amgen Inc. Presents at ATX West 2021, Aug-10-2021 . Venue: Anahiem, California, United States. Speakers: Khaudeja Bano, Executive Medical Dire...

Neutral

Amgen Inc. Presents at Reuters Total Health Vir...

2021-08-05 10:39:00

Amgen Inc. Presents at Reuters Total Health Virtual Global Conference, Nov-18-2021 12:15 PM. Speakers: Robert A. Bradway, Chairman, CEO & President.

Neutral

Amgen Inc. Presents at Pharma & Patient USA, No...

2021-08-05 08:52:00

Amgen Inc. Presents at Pharma & Patient USA, Nov-03-2021 11:00 AM. Speakers: Samantha Reyes, Patient Engagement Lead, Senior Manager.

Neutral

Amgen Inc. Presents at Pharma Europe, Oct-18-20...

2021-08-05 08:20:00

Amgen Inc. Presents at Pharma Europe, Oct-18-2021 10:15 AM. Speakers: Chris Mann, Head of Commercial Excellence, UK & Ireland.

Neutral

Reuters Events, Pharma Europe, Oct 11, 2021 thr...

2021-08-05 03:58:00

Reuters Events, Pharma Europe, Oct 11, 2021 through Oct 22, 2021.

Neutral

Reuters Events, Pharma & Patient USA, Nov 02, 2...

2021-08-05 03:58:00

Reuters Events, Pharma & Patient USA, Nov 02, 2021 through Nov 04, 2021.

Neutral

Reuters Events, Reuters Total Health Virtual Gl...

2021-08-05 03:58:00

Reuters Events, Reuters Total Health Virtual Global Conference, Nov 15, 2021 through Nov 18, 2021.

Positive

Amgen Inc. has announced a Fixed-Income Offering.

2021-08-05 00:00:00

Amgen Inc. has announced a Fixed-Income Offering. Security Name: Fixed Rate Senior Subordinated Unsecured Notes due 2028 Security Type: Co...

Positive

Amgen Inc. has announced a Fixed-Income Offering.

2021-08-05 00:00:00

Amgen Inc. has announced a Fixed-Income Offering. Security Name: Fixed Rate Senior Subordinated Unsecured Notes due 2032 Security Type: Co...

Positive

Amgen Inc. has announced a Fixed-Income Offering.

2021-08-05 00:00:00

Amgen Inc. has announced a Fixed-Income Offering. Security Name: Fixed Rate Senior Subordinated Unsecured Notes due 2041 Security Type: Co...

Positive

Amgen Inc. has announced a Fixed-Income Offering.

2021-08-05 00:00:00

Amgen Inc. has announced a Fixed-Income Offering. Security Name: Fixed Rate Senior Subordinated Unsecured Notes due 2052 Security Type: Co...

Negative

Deutsche Bank Securities Inc. has been added as...

2021-08-05 00:00:00

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

Negative

HSBC Securities (USA) Inc. has been added as th...

2021-08-05 00:00:00

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

Negative

J.P. Morgan Securities LLC has been added as th...

2021-08-05 00:00:00

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

Negative

MUFG Securities Americas Inc. has been added as...

2021-08-05 00:00:00

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

Positive

Amgen Inc. has completed a Fixed-Income Offerin...

2021-08-05 00:00:00

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.341738 billion. Security Name: 3% Senior Subordinated Unsecured Notes ...

Negative

Deutsche Bank Securities Inc. has been added as...

2021-08-05 00:00:00

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

Negative

HSBC Securities (USA) Inc. has been added as th...

2021-08-05 00:00:00

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

Negative

J.P. Morgan Securities LLC has been added as th...

2021-08-05 00:00:00

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

Negative

MUFG Securities Americas Inc. has been added as...

2021-08-05 00:00:00

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

Positive

Amgen Inc. has completed a Fixed-Income Offerin...

2021-08-05 00:00:00

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.146493 billion. Security Name: 2.800% Senior Subordinated Unsecured No...

Negative

Deutsche Bank Securities Inc. has been added as...

2021-08-05 00:00:00

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

Negative

HSBC Securities (USA) Inc. has been added as th...

2021-08-05 00:00:00

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

Negative

J.P. Morgan Securities LLC has been added as th...

2021-08-05 00:00:00

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

Negative

MUFG Securities Americas Inc. has been added as...

2021-08-05 00:00:00

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

Positive

Amgen Inc. has completed a Fixed-Income Offerin...

2021-08-05 00:00:00

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.2416 billion. Security Name: 2% Senior Subordinated Unsecured Notes du...

Negative

Deutsche Bank Securities Inc. has been added as...

2021-08-05 00:00:00

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

Negative

HSBC Securities (USA) Inc. has been added as th...

2021-08-05 00:00:00

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

Negative

J.P. Morgan Securities LLC has been added as th...

2021-08-05 00:00:00

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

Negative

MUFG Securities Americas Inc. has been added as...

2021-08-05 00:00:00

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

Positive

Amgen Inc. has completed a Fixed-Income Offerin...

2021-08-05 00:00:00

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.24885 billion. Security Name: 1% Senior Subordinated Unsecured Notes d...

Neutral

Tranche Update on Amgen Inc. (NasdaqGS:AMGN)'s ...

2021-08-04 10:11:00

From April 1, 2021 to June 30, 2021, the company has repurchased 6,518,985 shares, representing 1.13% for $1,591.94 million. With this, the co...

Negative

Amgen Inc. Revises Earnings Guidance for the Fu...

2021-08-03 20:01:00

Amgen Inc. revised earnings guidance for the full year 2021. For the period, the company's EPS in the range of $8.84 to $9.90. Previously, the...

Positive

Amgen Declares Dividend for the Third Quarter o...

2021-07-30 20:00:00

Amgen announced that its Board of Directors declared a $1.76 per share dividend for the third quarter of 2021. The dividend will be paid on Se...

Neutral

Amgen Inc. to Report Q2, 2021 Results on Aug 03, 2021

2021-07-30 00:00:00

Amgen Inc. announced that they will report Q2, 2021 results After-Market on Aug 03, 2021

Positive

Amgen Inc., $ 1.76, Cash Dividend, Aug-16-2021

2021-07-30 00:00:00

Amgen Inc., $ 1.76, Cash Dividend, Aug-16-2021

Neutral

Amgen Inc. Presents at Annual User Conference C...

2021-07-29 23:46:00

Amgen Inc. Presents at Annual User Conference Cvent CONNECT, Aug-03-2021 08:00 AM. Speakers: Toby Frowen, Global Meetings Management Lead.

Negative

Amgen Announces Appointment of S. Omar Ishrak t...

2021-07-29 23:10:00

Amgen announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak will also serve as a member of ...

Neutral

Informa plc, MD&M West conference, Aug 10, 202...

2021-07-28 14:00:00

Informa plc, MD&M West conference, Aug 10, 2021 through Aug 12, 2021. Venue: Anaheim Convention Cente, Anahiem, California, United States.

Positive

Amgen Inc. (NasdaqGS:AMGN) announced an agreeme...

2021-07-27 00:00:00

Amgen Inc. (NasdaqGS:AMGN) announced an agreement to acquire TeneoBio, Inc. from Lightspeed Venture Partners, Sutter Hill Ventures and others ...

Neutral

Amgen Inc. Presents at KMWorld 2021, Nov-15-2021

2021-07-22 16:50:00

Amgen Inc. Presents at KMWorld 2021, Nov-15-2021 . Venue: JW Marriott, Washington, District Of Columbia, United States. Speakers: Brian McBree...

Neutral

Information Today, Inc., KMWorld 2021, Nov 15, ...

2021-07-22 14:53:00

Information Today, Inc., KMWorld 2021, Nov 15, 2021 through Nov 18, 2021. Venue: JW Marriott, Washington, District Of Columbia, United States.

Neutral

Terrapinn Holdings Ltd, World Vaccine & Immunot...

2021-07-22 01:45:00

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay R...

Neutral

Informa plc, EU Merger Control 2021, Sep 28, 2021

2021-07-20 00:00:00

Informa plc, EU Merger Control 2021, Sep 28, 2021.

Neutral

Amgen Inc. Presents at EU Merger Control 2021, ...

2021-07-20 00:00:00

Amgen Inc. Presents at EU Merger Control 2021, Sep-28-2021 10:50 AM. Speakers: Nicolas Pourbaix, Senior Counsel.

Neutral

Amgen Inc. Presents at Cambridge Health Institu...

2021-07-16 13:36:00

Amgen Inc. Presents at Cambridge Health Institute PEGS Virtual Conference, Jul-19-2021 through Jul-22-2021. Presentation Date & Speakers: Jul-...

Neutral

Cambridge Healthtech Institute, Inc., Cambridge...

2021-07-16 12:52:00

Cambridge Healthtech Institute, Inc., Cambridge Health Institute PEGS Virtual Conference, Jul 19, 2021 through Jul 22, 2021.

Neutral

Amgen Inc. Presents at CannPack West 2021, Aug-10-2021

2021-07-15 14:57:00

Amgen Inc. Presents at CannPack West 2021, Aug-10-2021 . Speakers: SUSAN NEADLE, Executive Director & Head of Combination Products, Devices, D...

Neutral

Amgen Inc. Presents at 2021 FDA/PDA Joint Regul...

2021-07-15 14:25:00

Amgen Inc. Presents at 2021 FDA/PDA Joint Regulatory Conference, Sep-27-2021 . Speakers: Kathy A. Demarest, Executive Director of Site Quality.

Neutral

Parenteral Drug Association, U.S. Food and Drug...

2021-07-15 13:17:00

Parenteral Drug Association, U.S. Food and Drug Administration, 2021 FDA/PDA Joint Regulatory Conference, Sep 27, 2021 through Sep 29, 2021.

Neutral

Informa Markets Limited, CannPack West 2021, Au...

2021-07-15 13:02:00

Informa Markets Limited, CannPack West 2021, Aug 10, 2021 through Aug 12, 2021.

Positive

Amgen Announces U.S. Food and Drug Administrati...

2021-07-08 06:00:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Revie...

Neutral

Amgen Inc., Q2 2021 Earnings Call, Aug 03, 2021

2021-06-30 13:01:00

Amgen Inc., Q2 2021 Earnings Call, Aug 03, 2021

Neutral

Amgen Inc. Presents at The European Pharma Law ...

2021-06-29 16:36:00

Amgen Inc. Presents at The European Pharma Law Academy, Sep-06-2021 through Sep-10-2021. Presentation Date & Speakers: Sep-06-2021, Robert Jen...

Neutral

Amgen Inc. Presents at 5th LSX USA Congress & CEO Forums, Jun-21-2022

2022-06-16 19:39:00

Amgen Inc. Presents at 5th LSX USA Congress & CEO Forums, Jun-21-2022 . Venue: Boston, United States.

Neutral

Amgen Inc. Reaffirms Revenue Guidance for the Year 2022

2022-06-15 17:40:00

Amgen Inc. reaffirmed revenue guidance for the year 2022. The company reaffirmed going to 2022 revenue ranges despite by headwinds.

Neutral

Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 10:40 AM

2022-06-10 20:15:00

Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 10:40 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: David M. Reese, Executive Vice President of Research & Development, Peter H. Griffith, Executive VP & CFO.

Neutral

Amgen Inc. Presents at Antibody Engineering & Therapeutics Europe, Jun-09-2022 03:25 PM

2022-06-06 15:28:00

Amgen Inc. Presents at Antibody Engineering & Therapeutics Europe, Jun-09-2022 03:25 PM. Venue: Amsterdam, Netherlands. Speakers: Brian Avanzino, Scientist III.

Positive

Amgen Inc. Announces U.S. Food and Drug Administration Approves RIABNI

2022-06-06 13:00:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. RIABNI is already approved for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (also called Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). RIABNI, a CD20-directed cytolytic antibody, was proven to be highly similar to, with no clinically meaningful differences in safety or efficacy from, Rituxan (rituximab) based on totality of evidence, which included comparative analytical, non-clinical and clinical data. The randomized, double-blind, comparative clinical study compared the efficacy, safety, pharmacokinetics and immunogenicity of RIABNI versus rituximab reference product (RP) in patients with moderate to severe RA. Overall, 311 patients were randomized and treated with RIABNI, rituximab RP approved in the EU (rituximab-EU) or rituximab RP approved in the US (rituximab-US). The rituximab-US group transitioned to RIABNI in period 2 of the study. The primary efficacy endpoint, the change in disease activity score 28 using C-reactive protein (DAS28-CRP) from baseline at week 24, was within the predefined equivalence margin indicating equivalence in clinical efficacy between RIABNI and rituximab RP. Safety, pharmacokinetics and immunogenicity of RIABNI were similar to rituximab RP.

Positive

Amgen and Takeda Pharmaceutical Company Announces New Data from the Phase 3 Paradigm Clinical Trial of Vectibix® (Panitumumab) in Japanese Patients

2022-06-05 12:00:00

Amgen and Takeda Pharmaceutical Company announced that new data from the Phase 3 PARADIGM clinical trial of Vectibix® (panitumumab) in Japanese patients with previously untreated unresectable wild-type RAS metastatic colorectal cancer (mCRC) are being featured during the June 5 Plenary Session (Abstract #LBA1) of the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and online. PARADIGM is a randomized trial conducted in Japan comparing the efficacy and safety of Vectibix plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in chemotherapy-naive patients with unresectable advanced mCRC (n=823). This trial was conducted by Takeda. This is the first prospective trial to evaluate treatment options for patients with wild-type RAS mCRC and left-side primary tumor (descending colon, sigmoid colon, and rectum). The results of the trial showed that the mFOLFOX6 + Vectibix combination provides a statistically significant improvement in overall survival (OS) over the mFOLFOX6 + bevacizumab combination in patients with a left-sided primary tumor or regardless of tumor locations (median OS for left-sided tumors: 37.9 vs. 34.3 months, HR=0.82 [95.798% CI: 0.68-0.99], p=0.031, overall median OS: 36.2 vs. 31.3 months, HR=0.84 [95% CI: 0.72-0.98], p=0.030). The safety profile of Vectibix in this study was similar to clinical study results previously published.

Neutral

Amgen Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 09:30 AM

2022-06-03 20:00:00

Amgen Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 09:30 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Murdo Gordon, Executive VP of Global Commercial Operations.

Neutral

I.I.R Ltd., Antibody Engineering & Therapeutics Europe, Jun 07, 2022 through Jun 09, 2022

2022-06-01 12:03:00

I.I.R Ltd., Antibody Engineering & Therapeutics Europe, Jun 07, 2022 through Jun 09, 2022. Venue: Amsterdam, Netherlands.

Positive

Amgen Announces Positive Topline Phase 2 Data for Investigational Olpasiran in Adults with Elevated Lipoprotein(a)

2022-05-31 13:00:00

Amgen announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA designed to lower the body's production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of cardiovascular events. In the double-blind placebo-controlled treatment period, olpasiran was administered up to 225 mg subcutaneously every 12 weeks to patients with a median baseline Lp(a) of approximately 260 nmol/L. These data demonstrated a significant reduction from baseline in Lp(a) of up to or greater than 90% at week 36 (primary endpoint) and week 48 (end of treatment period) for the majority of doses. No new safety concerns were identified during this treatment period.

Neutral

Amgen Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022

2022-05-28 18:13:00

Amgen Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022 . Venue: Chicago, Illinois, United States. Speakers: Cathy Critchlow, Vice President, R&D Data Strategy, Freda Cooner, Director, Statistics, Center for Design and Analysis (CfDA), Khaudeja Bano, Vice President, Combination Product Quality, Leah Christl, Exec Director, Global Biosimilars Regulatory Affairs & Regulatory, Megan Doyle, Global Policy Lead, Digital Health, Diagnostics, Oncology, Monica Batra, Executive Director, Global Regulatory Affairs - Oncology, Nina Cauchon, Director Regulatory Affairs CMC, Wenying Du, Director, Global Regulatory Lead.

Neutral

Amgen Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022

2022-05-26 21:00:00

Amgen Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022. Venue: McCormick Place, Chicago, Illinois, United States. Presentation Date(s): Jun-04-2022. Jun-05-2022. Jun-06-2022. Jun-07-2022.

Neutral

Amgen Inc. Presents at CHCI Issue Summits, May-17-2022

2022-05-16 18:03:00

Amgen Inc. Presents at CHCI Issue Summits, May-17-2022 . Venue: 600 14th Street NW, Washington, District Of Columbia, United States. Speakers: Racquel Racadio, Director, Representation in Clinical Research (RISE).

Neutral

Amgen Inc. Presents at BIO International Convention 2022, Jun-13-2022

2022-05-15 00:00:00

Amgen Inc. Presents at BIO International Convention 2022, Jun-13-2022 . Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Helen Kim, Executive Director, External R&D, Paul Neureiter, Executive Director for International Government Affairs and Trade Policy.

Neutral

Amgen Inc. Presents at Preclinical Immuno-Oncology: Online Seminar, May-18-2022

2022-05-13 02:43:00

Amgen Inc. Presents at Preclinical Immuno-Oncology: Online Seminar, May-18-2022. Presentation Date & Speakers: May-18-2022, Deepali Sawant, Principal Scientist, Oncology, Stephanie Casey Parks, Senior Scientist, Oncology, Stephanie Casey Parks, Senior Scientist, Oncology.

Neutral

Amgen Inc. Presents at American Association of Clinical Endocrinology (AACE) Annual Meeting, May-12-2022

2022-05-12 18:39:00

Amgen Inc. Presents at American Association of Clinical Endocrinology (AACE) Annual Meeting, May-12-2022 . Venue: San Diego, United States. Speakers: Cynthia Deignan, Medical Director.

Neutral

Congressional Hispanic Caucus Institute, CHCI Issue Summits, May 17, 2022 through May 18, 2022

2022-05-10 19:40:00

Congressional Hispanic Caucus Institute, CHCI Issue Summits, May 17, 2022 through May 18, 2022. Venue: 600 14th Street NW, Washington, District Of Columbia, United States.

Neutral

patientNOW, Inc, Rx Marketing Group, 17th Edition of the Music City Symposium for Cosmetic Advances & Laser Education, May 11, 2022 through May 15, 2022

2022-05-05 12:30:00

patientNOW, Inc, Rx Marketing Group, 17th Edition of the Music City Symposium for Cosmetic Advances & Laser Education, May 11, 2022 through May 15, 2022. Venue: Nashville, Tennessee, United States.

Neutral

Tranche Update on Amgen Inc. (NasdaqGS:AMGN)'s Equity Buyback Plan announced on April 21, 2011.

2022-04-28 10:19:00

From January 1, 2022 to March 31, 2022, the company has repurchased 24,622,497 shares, representing 4.41% for $6,310.11 million. With this, the company has completed the repurchase of 422,852,948 shares, representing 56.62% for $60,023.2 million under the buyback announced on April 21, 2011.

Neutral

Amgen Inc. Provides Earnings Guidance for the Year 2022

2022-04-27 20:20:00

Amgen Inc. provided earnings guidance for the year 2022. For the year, the company expects total revenues in the range of $25.4 billion to $26.5 billion. On a GAAP basis, EPS in the range of $12.53 to $13.58 and a tax rate in the range of 10.5% to 12.0%.

Positive

Amgen Announces Top-Line Results from Two Repatha® (Evolocumab) Open Label Extension (OLE) Studies to the Phase 3 Fourier Cardiovascular Outcomes Trial

2022-04-27 13:00:00

Amgen announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER cardiovascular outcomes trial. The studies were designed to assess the long-term safety and tolerability of Repatha over five years in adults with clinically evident atherosclerotic cardiovascular disease. The FOURIER-OLE (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated – Risk-Open Label Extension) studies were composed of study 20130295 (NCT02867813) with 5,035 patients enrolled in Eastern Europe and the United States and study 20160250 (NCT03080935) with 1,600 patients enrolled in Western Europe. Both studies showed that Repatha, administered at 140 mg every two weeks or 420 mg monthly, was safe and well-tolerated. In the OLE studies, patients received Repatha for approximately 5 years, with some patients receiving Repatha for up to 8 1/2 years in aggregate across the FOURIER and OLE studies. No new long-term safety findings were observed. In addition, medically significant and sustained reduction in low-density lipoprotein cholesterol (LDL-C) levels were observed, with more than 85% of patients achieving an LDL-C level of <40 mg/dL during the OLE period. Detailed study results will be shared with regulatory authorities and submitted for presentation at an upcoming medical congress later this year. Prolonged LDL-C reduction with Repatha is also being studied in the ongoing VESALIUS-CV (NCT03872401) outcomes trial. Repatha® Cardiovascular Open-Label Extension (FOURIER-OLE) Study Design: FOURIER (20110118) was a randomized placebo-controlled study of evolocumab, in patients with clinically evident atherosclerotic CVD on stable effective statin therapy. FOURIER-OLE (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated – Risk-Open Label Extension) were multicenter, open-label extension (OLE) studies designed to assess the extended long-term safety of evolocumab in subjects who completed the FOURIER study (20110118). The FOURIER-OLE is composed of studies 20130295 and 20160250, which enrolled 5,035 and 1,600 subjects who completed FOURIER study (20110118) to receive open-label evolocumab and were followed up for a median of 5 and 4.6 years, respectively. PROFICIO Program: FOURIER is part of Amgen's PROFICIO (Program to Reduce LDL-C and cardiovascular Outcomes Following Inhibition of PCSK9 In different pOpulations) program of clinical studies investigating the impact of Repatha® on LDL-C and CVD across multiple populations at high CV risk, including those managed by statins, statin-intolerant patients, those with genetic disorders and patients with atherosclerosis. To date, the PROFICIO program consists of 36 trials including more than 38,000 patients worldwide.

Neutral

Amgen Inc. Presents at PEGS Boston Conference 2022, May-04-2022 09:00 AM

2022-04-23 07:37:00

Amgen Inc. Presents at PEGS Boston Conference 2022, May-04-2022 09:00 AM. Venue: Boston, Massachusetts, United States. Speakers: Katherine Harris, Vice Presiden.

Neutral

Amgen Inc. to Report Q1, 2022 Results on Apr 27, 2022

2022-04-22 20:00:00

Amgen Inc. announced that they will report Q1, 2022 results After-Market on Apr 27, 2022

Neutral

Amgen Inc. Presents at 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr-26-2022

2022-04-21 15:29:00

Amgen Inc. Presents at 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr-26-2022 . Venue: Boston, Massachusetts, United States. Speakers: Bram Estes, Senior Scientist.

Neutral

Hanson Wade Limited, 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr 26, 2022 through Apr 28, 2022

2022-04-21 09:39:00

Hanson Wade Limited, 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr 26, 2022 through Apr 28, 2022. Venue: Boston, Massachusetts, United States.

Positive

Amgen Announces Positive Top-Line Results from Phase 3 Study of ABP 654 Compared to STELARA® (Ustekinumab) in Adult Patients with Moderate to Severe Plaque Psoriasis

2022-04-18 20:00:00

Amgen announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA® (ustekinumab) in adult patients with moderate to severe plaque psoriasis. The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and STELARA. The primary analysis evaluated the percentage improvement from baseline to week 12 of psoriasis area severity index (PASI), which showed a mean difference of percentage improvement between ABP 654 and STELARA of 0.14, which was within the prespecified margins. The safety profile of ABP 654 was comparable to STELARA. ABP 654 is being developed as a biosimilar candidate to STELARA, an approved human interleukin-12 and interleukin-23 antagonist indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients (6 years or older) who are candidates for phototherapy or systemic therapy, active psoriatic arthritis in adults, as well as for adult patients with moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis. Amgen has a total of 11 biosimilars in its portfolio, including five that have been approved by the U.S. Food and Drug Administration (FDA) and three that are approved in the EU.

Neutral

Amgen Inc. Presents at Drug Discovery Chemistry Conference 2022, Apr-18-2022 through Apr-21-2022

2022-04-14 17:07:00

Amgen Inc. Presents at Drug Discovery Chemistry Conference 2022, Apr-18-2022 through Apr-21-2022. Presentation Date & Speakers: Apr-18-2022, Ryan Potts, Executive Director and Head, Induced Proximity Platform. Apr-19-2022, Ryan Potts, Executive Director and Head, Induced Proximity Platform. Apr-20-2022, Ryan P. Wurz, Principal Scientist, Medicinal Chemistry.

Neutral

Cambridge Innovation Institute, LLC, Drug Discovery Chemistry Conference 2022, Apr 18, 2022 through Apr 21, 2022

2022-04-14 12:01:00

Cambridge Innovation Institute, LLC, Drug Discovery Chemistry Conference 2022, Apr 18, 2022 through Apr 21, 2022.

Neutral

Amgen Inc., Q1 2022 Earnings Call, Apr 27, 2022

2022-04-13 00:00:00

Amgen Inc., Q1 2022 Earnings Call, Apr 27, 2022

Positive

Amgen Inc. Announces the Presentation of Long-Term Efficacy and Safety Data from the CodeBreaK 100 Phase 1/2 Trial in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer Who Received LUMAKRAS

2022-04-10 16:00:00

Amgen announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who received LUMAKRAS® (sotorasib). The two-year follow-up data will be presented orally as part of a clinical trials plenary session at the American Association for Cancer Research (AACR) annual meeting on April 10, 2022. LUMAKRAS is the first and only KRASG12C inhibitor to-date to show long-term clinical benefit and overall survival in patients with NSCLC harboring the KRAS G12C mutation. In this long-term, two-year analysis of 174 heavily pre-treated patients (172 with baseline measurable lesion(s)), LUMAKRAS demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate (DCR) of 83.7% and median duration of response (DOR) of 12.3 months. Five patients achieved complete responses and 65 patients achieved partial responses. The results also showed median progression-free survival (PFS) of 6.3 months and overall survival (OS) of 12.5 months with 32.5% of patients still alive at two years. No new safety signals for LUMAKRAS were identified with the long-term follow-up. In May 2021, LUMAKRAS was the first KRASG12C inhibitor to receive regulatory approval with its approval in the U.S., under accelerated approval. LUMAKRAS is now approved in 39 countries. About LUMAKRAS®/LUMYKRAS® (sotorasib): Amgen took on one of the toughest challenges of the last 40 years in cancer research by developing LUMAKRAS/LUMYKRAS, a KRASG12C inhibitor. LUMAKRAS/LUMYKRAS has demonstrated a positive benefit-risk profile with rapid, deep, and durable anticancer activity in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation with a once daily oral formulation. Amgen is progressing the and broadest global KRASG12C inhibitor development program with unparalleled speed and exploring more than 10 sotorasib combination regimens, including triplets, with clinical trial sites spanning five continents. To date, over 4,000 patients around the world have received LUMAKRAS/LUMYKRAS through the clinical development program and commercial use. In May 2021, LUMAKRAS was the first KRASG12C inhibitor to receive regulatory approval with its approval in the U.S., under accelerated approval. LUMAKRAS/LUMYKRAS is also approved in the European Union, Japan, United Arab Emirates, South Korea and Switzerland and in Australia, Brazil, Canada, and Great Britain under the FDA'sProject Orbis. Through Project Orbis, Amgen also has Marketing Authorization Applications (MAAs) for sotorasib in review in Israel and Singapore. Additionally,?Amgen?has submitted MAAs in Argentina, Colombia, Hong Kong, Kuwait, Malaysia, Mexico, Qatar, Saudi Arabia, Taiwan, Thailand and Turkey. LUMAKRAS/LUMYKRAS is also being studied in multiple other solid tumors. About Non-Small Cell Lung Cancer and the KRAS G12C Mutation: Lung cancer is the leading cause of cancer-related deaths worldwide, and it accounts for more deaths worldwide than colon cancer, breast cancer and prostate cancer combined. Overall survival rates for NSCLC are improving but remain poor for patients with advanced disease and 5-year survival is only 7% for those with metastatic disease. KRAS G12C is the most common KRAS mutation in NSCLC. About 13% of patients with NSCLC harbor the KRAS G12C mutation. Unmet medical need remains high and treatment options are limited for NSCLC patients with the KRAS G12C mutation whose first-line treatment has failed to work or has stopped working. The outcomes with other approved therapies are suboptimal, with a median progression-free survival of approximately four months following second-line treatment of KRAS G12C-mutated NSCLC. About CodeBreaK: The CodeBreaK clinical development program for Amgen's drug sotorasib is designed to study patients with an advanced solid tumor with the KRAS G12C mutation and address the longstanding unmet medical need for these cancers.

Neutral

Amgen Inc., Annual General Meeting, May 17, 2022

2022-04-05 20:11:00

Amgen Inc., Annual General Meeting, May 17, 2022, at 11:00 Pacific Standard Time. Agenda: To elect twelve directors to the Board of Directors of Amgen for a term of office expiring at the 2023 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Charles M. Holley, Jr., Dr. S. Omar Ishrak, Dr. Tyler Jacks, Ms. Ellen J. Kullman, Ms. Amy E. Miles, Dr. Ronald D. Sugar, and Dr. R. Sanders Williams; to hold an advisory vote to approve company's executive compensation; to ratify the selection of Ernst & Young LLP as company's independent registered public accountants for the fiscal year ending December 31, 2022; and to transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.

Neutral

Amgen Inc. - Shareholder/Analyst Call

2022-04-05 20:11:00

AGM

Neutral

Amgen Inc. Presents at Pharma Manufacturing World Summit, Mar-29-2022

2022-03-29 08:36:00

Amgen Inc. Presents at Pharma Manufacturing World Summit, Mar-29-2022 . Venue: Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Arleen Paulino, Senior Vice President of Manufacturing, Heather Nunn, Process Development Principal Scientist, Thomas Seewoester, VP External Supply Operations.

Neutral

Amgen Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 09:20 AM

2022-03-22 05:03:00

Amgen Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 09:20 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Arvind Sood, Vice President of Investor Relations, David M. Reese, Executive Vice President of Research & Development, Peter H. Griffith, Executive VP & CFO.

Neutral

Executive Platforms Inc., Pharma Manufacturing World Summit, Mar 29, 2022 through Mar 30, 2022

2022-03-21 14:57:00

Executive Platforms Inc., Pharma Manufacturing World Summit, Mar 29, 2022 through Mar 30, 2022. Venue: Boston Marriott Copley Place, Boston, Massachusetts, United States.

Neutral

Amgen Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022

2022-03-08 21:30:00

Amgen Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States. Presentation Date(s): Apr-10-2022. Apr-11-2022. Apr-12-2022.

Positive

Amgen Inc., $ 1.94, Cash Dividend, May-16-2022

2022-03-02 00:00:00

Amgen Inc., $ 1.94, Cash Dividend, May-16-2022

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

Oxford Global Marketing Ltd., Preclinical Immuno-Oncology: Online Seminar, May 18, 2022

2022-02-16 04:05:00

Oxford Global Marketing Ltd., Preclinical Immuno-Oncology: Online Seminar, May 18, 2022.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Amgen Inc. Provides Earnings Guidance for 2022

2022-02-08 13:00:00

Amgen Inc. provides earnings guidance for 2022. For 2022, the company is expecting revenue of $25.4 billion to $26.5 billion, an EPS of $17 to $18.

Neutral

Amgen Inc. Presents at 2022 OBIO Investment Summit, Feb-09-2022 12:00 PM

2022-02-08 08:05:00

Amgen Inc. Presents at 2022 OBIO Investment Summit, Feb-09-2022 12:00 PM. Speakers: Angela Behboodi, Philip Tagari.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

Amgen Inc. Presents at SCOPE Summit 2022, Feb-09-2022 11:25 AM

2022-02-04 08:35:00

Amgen Inc. Presents at SCOPE Summit 2022, Feb-09-2022 11:25 AM. Venue: Orlanda, Florida, United States. Speakers: Michael Morozewicz, Senior Manager, Biomedical Data Stewardship.

Positive

Amgen Inc. and Plexium Inc. Announces Multi-Year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degradation Therapies

2022-02-03 14:00:00

Amgen Inc. and Plexium, Inc. announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets. The multi-year collaboration supports the discovery of novel molecular glue therapeutics leveraging insights from Amgen's expertise in developing multispecific molecules. Under the terms of the agreement, the collaboration will initially focus on two programs with Amgen holding options to add additional programs. Plexium is eligible to receive over $500 million in success-based target access, pre-clinical, clinical, regulatory and commercial milestones, as well as tiered single-digit royalty payments, if all options are exercised. Amgen has a commercial license to each program that advances to a predefined preclinical stage of development and will be responsible for global development and commercialization. The partnership will focus on expanding targeted protein degradation opportunities through discovery of previously unrecognized molecular glues or monovalent degraders. These molecules work through a concept of induced proximity that take advantage of the normal biology of a cell to bring two proteins together to drive protein degradation. This collaboration incorporates Plexium's comprehensive targeted protein degradation platform, powered by a proprietary high-throughput cell-based screening technology that enables the discovery of novel molecular glue therapies.

Neutral

Ontario Bioscience Innovation Organization, 2022 OBIO Investment Summit, Feb 09, 2022 through Feb 11, 2022

2022-01-26 12:49:00

Ontario Bioscience Innovation Organization, 2022 OBIO Investment Summit, Feb 09, 2022 through Feb 11, 2022.

Neutral

Amgen Inc. to Report Q4, 2021 Results on Feb 07, 2022

2022-01-26 02:31:00

Amgen Inc. announced that they will report Q4, 2021 results at 4:00 PM, Eastern Standard Time on Feb 07, 2022

Neutral

Amgen Inc. - Special Call

2022-01-26 02:31:00

To review the company's strategy, operations, pipeline, research capabilities and growth outlook

Neutral

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Neutral

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Mass General Brigham Incorporated, World Medical Innovation Forum, May 02, 2022 through May 04, 2022

2022-01-06 16:02:00

Mass General Brigham Incorporated, World Medical Innovation Forum, May 02, 2022 through May 04, 2022. Venue: Westin Copley, Boston, Massachusetts, United States.

Neutral

Amgen Inc. Presents at World Medical Innovation Forum, May-02-2022

2022-01-06 16:02:00

Amgen Inc. Presents at World Medical Innovation Forum, May-02-2022 . Venue: Westin Copley, Boston, Massachusetts, United States. Speakers: Robert A. Bradway, Chairman, CEO & President.

Positive

Amgen Announces FDA Approves Otezla® (Apremilast)

2021-12-20 21:25:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. With this expanded indication, Otezla is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate and severe. The FDA approval is based on findings from the Phase 3 ADVANCE trial, in which five times as many adults with mild to moderate plaque psoriasis receiving oral Otezla 30 mg twice daily achieved the primary endpoint of Static Physician's Global Assessment (sPGA) response at week 16 compared to placebo (21.6% versus 4.1%, p<0.0001), a difference that was statistically significant. Otezla also demonstrated statistically significant improvements in key symptoms, such as Whole Body Itch NRS response (43.2% versus 18.6%), and a difficult-to-treat area, the scalp, measured by Scalp Physician's Global Assessment (ScPGA) response (44% versus 16.6%), at week 16 compared to placebo. Improvements in sPGA response, Whole Body Itch NRS and ScPGA response were observed as early as week 2 and maintained through week 32. The adverse events observed in the trial were consistent with the known safety profile of Otezla. The most commonly reported (=5%) treatment-emergent adverse events with Otezla treatment were diarrhea, headache, nausea and nasopharyngitis. Approximately 8 million people in the U.S. have plaque psoriasis, and 5 million people in the U.S. have mild to moderate disease. Despite the prevalence and treatment advances in recent years, a significant unmet need remains, particularly for people with mild to moderate plaque psoriasis or those who experience persistent symptoms despite topical treatment.

Positive

Amgen Announces That the U.S. Food and Drug Administration Has Approved Amgen and Astrazeneca's Tezspire in the U.S. for Severe Asthma

2021-12-17 21:30:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Tezspire was approved following a Priority Review by the FDA and based on results from the PATHFINDER clinical trial program. The application included results from the pivotal NAVIGATOR Phase 3 trial in which Tezspire demonstrated superiority across every primary and key secondary endpoint in patients with severe asthma, compared to placebo, when added to standard therapy. Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine.3 It is the first and only biologic to consistently and significantly reduce asthma exacerbations across Phase 2 and 3 clinical trials, which included a broad population of severe asthma patients irrespective of key biomarkers, including blood eosinophil counts, allergic status and fractional exhaled nitric oxide (FeNO). Tezspire is the first and only biologic for severe asthma that does not have a phenotype—eosinophilic or allergic—or biomarker limitation within its approved label. In clinical studies of Tezspire, the most common adverse reactions were nasopharyngitis, upper respiratory tract infection and headache. Tezspire is under regulatory review in the EU, Japan and several other countries around the world. Amgen and AstraZeneca are committed to providing appropriate patients who are prescribed Tezspire with affordable access to the medicine. Patients, caregivers and physicians who need support or resources can contact the Tezspire Together program starting on December 20 at 8:00 a.m. ET by calling 1-888-TZSPIRE (1-888-897-7473). Tezspire is a first-in-class medicine indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Tezspire is not indicated for the relief of acute bronchospasm or status asthmaticus. WARNINGS AND PRECAUTIONS: Hypersensitivity Reactions: Hypersensitivity reactions (e.g., rash and allergic conjunctivitis) can occur following administration of TEZSPIRE. These reactions can occur within hours of administration, but in some instances have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, initiate appropriate treatment as clinically indicated and then consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE. Acute Asthma Symptoms or Deteriorating Disease: TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus. Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. Parasitic (Helminth) Infection: It is unknown if TEZSPIRE will influence a patient's response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves. Live Attenuated Vaccines: The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE. ADVERSE REACTIONS: The most common adverse reactions (incidence =3%) are pharyngitis, arthralgia, and back pain. USE IN SPECIFIC POPULATIONS: There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as Tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

Positive

Syngene International Limited Announces Extension of Its Long-Standing Multi-Discipline Research Collaboration with Amgen Inc

2021-12-16 06:07:00

Syngene International Limited announced the extension of its long-standing multi-discipline research collaboration with Amgen Inc. The contract is currently extended until the end of 2026 and its scope includes integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. In addition to operating the existing Syngene Amgen R&D Center (SARC), under the new contract, Syngene will also build and operate a dedicated laboratory which will enable R&D project acceleration. SARC was established in 2016 and Syngene announced expansion of the original dedicated centre in 2017. It currently consists of 60,000 sq. ft of floor space and a dedicated team of multi-disciplinary Syngene scientists who work closely with Amgen researchers around the world on the discovery and development of innovative medicines.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022

2021-12-10 06:32:00

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022. Venue: Chicago, Illinois, United States.

Neutral

Amgen Inc. Presents at BioFlorida Conference, Dec-09-2021 11:15 AM

2021-12-07 04:14:00

Amgen Inc. Presents at BioFlorida Conference, Dec-09-2021 11:15 AM. Venue: Renaissance Orlando at SeaWorld, 6677 Sea Harbor Dr, Orlando, Florida, United States. Speakers: David A. Piacquad, Senior Vice President.

Positive

Amgen Announces New Data Being Presented At ASH 2021

2021-12-06 21:00:00

Amgen announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rdAmerican Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, and virtually, from Dec. 11-14, 2021. Amgen will present data on its bispecific T-cell engager (BiTE®) platform, including BLINCYTO® (blinatumomab), as well as KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Updated data from the Phase 3 '215 trial in children with high-risk first relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) showed BLINCYTO improved event-free survival (EFS) and overall survival (OS) versus chemotherapy before allogeneic hematopoietic stem cell transplant (alloHSCT). The first presentation of safety and efficacy data with BLINCYTO administered subcutaneously in adults with relapsed or refractory B-ALL also demonstrated encouraging results. Additionally, results from the Phase 1b study investigating KYPROLIS in combination with vincristine, dexamethasone, PEG-asparaginase, daunorubicin (VXLD) induction therapy in children with relapsed or refractory ALL showing promising efficacy in highly advanced relapsed/refractory pediatric ALL will be presented in a poster discussion session. Analyses from the Pregnancy Surveillance Program (PSP) evaluating pregnancy and fetal outcomes of women exposed to Nplate highlighting no substantial safety concerns identified for mothers, fetuses and infants due to Nplate use during pregnancy will also be shared as an oral presentation on, Dec. 13, 2021. Study 20120215 is a Phase 3 open-label, multicenter, randomized, controlled trial evaluating event-free survival (EFS) after treatment with BLINCYTO compared with standard of care consolidation chemotherapy in pediatric patients with high-risk first-relapse B-cell ALL. In September 2019, the BLINCYTO arm showed superior efficacy on the primary endpoint of EFS, exceeding the prespecified stopping boundary; based on the recommendation from the Independent Data Monitoring Committee (DMC), Amgen terminated enrollment. Key secondary endpoints included overall survival and MRD response, adverse events (AEs), 100-day mortality after alloHSCT, incidence of anti-blinatumomab antibody formation, cumulative incidence of relapse. This is a global study that is being conducted as part of the PIP (Pediatric Investigation Plan) agreed to between Amgen and the EMA and is being conducted in Australia and various countries in the EU and Latin America.BLINCYTO is a BiTE® (bispecific T-cell engager) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers.

Positive

Amgen Declares 2022 First Quarter Dividend, Payable on March 8, 2022

2021-12-03 21:00:00

Amgen announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will be paid on March 8, 2022, to all stockholders of record as of the close of business on February 15, 2022. This represents a 10% increase from that paid in each of the previous four quarters.

Positive

Amgen Inc., $ 1.94, Cash Dividend, Feb-14-2022

2021-12-03 00:00:00

Amgen Inc., $ 1.94, Cash Dividend, Feb-14-2022

Positive

Amgen Inc. Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis

2021-12-01 21:00:00

Amgen Inc. announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with placebo, in the primary endpoint of the modified static Physician's Global Assessment of Genitalia (sPGA-G) response (defined as an sPGA-G score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16. In addition, all secondary endpoints were also met with meaningful and significant improvements in Genital Psoriasis Itch Numerical Rating Scale (GPI-NRS) response (defined as at least a 4-point reduction from baseline in GPI-NRS item score within the Genital Psoriasis Symptoms for subjects with a baseline score of = 4); affected body surface area (BSA) change from baseline; Dermatology Life Quality Index (DLQI) change from baseline; and static Physician's Global Assessment (sPGA) response (defined as sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16 with Otezla versus placebo. The type and rate of adverse events observed in this trial were consistent with the known safety profile of Otezla. The most commonly reported adverse events that occurred in at least 5% of patients in either treatment group were diarrhea, headache, nausea and nasopharyngitis. Patients completing the double-blind phase of the trial continued or switched to Otezla during the extension phase of the study and will be treated through week 32. The study is ongoing and is planned to complete in the first half of 2022. Detailed results from the 16-week double-blind phase of the study will be submitted for presentation at an upcoming medical conference.

Positive

FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse

2021-12-01 18:28:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. The expansion of the KYPROLIS prescribing information to include DARZALEX FASPRO plus dexamethasone was supported by the ongoing, Phase 2, non-randomized, open-label, multicenter PLEIADES trial evaluating the clinical benefit of DARZALEX FASPRO administered in combination with four standard-of-care treatment regimens in patients with multiple myeloma. Serious adverse reactions occurred in 27% of patients who received KYPROLIS in combination with DARZALEX FASPRO and dexamethasone. The most common adverse reactions (=20%) were upper respiratory tract infection, fatigue, insomnia, hypertension, diarrhea, cough, dyspnea, headache, pyrexia, nausea and peripheral edema. Fatal adverse reactions occurred in 3% of patients. Amgen will be submitting marketing applications globally. DARZALEX FASPRO® and DARZALEX® are registered trademarks of Johnson & Johnson.

Neutral

Amgen Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 05:10 PM

2021-11-24 21:05:00

Amgen Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 05:10 PM. Speakers: Rob Lenz, Senior Vice President of Global Development.

Neutral

Amgen Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Dec-01-2021 01:00 PM

2021-11-22 15:06:00

Amgen Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Dec-01-2021 01:00 PM. Venue: New York, New York, United States. Speakers: Arvind Sood, Vice President of Investor Relations, Murdo Gordon, Executive VP of Global Commercial Operations, Peter H. Griffith, Executive VP & CFO.

Positive

Amgen Announces the Committee for Medicinal Products for Human Use of the European Medicines Agency

2021-11-12 12:30:00

Amgen announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization of LUMYKRAS (sotorasib), known as LUMAKRAS in the U.S., for the treatment of adults with advanced non-small-cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. If the European Commission follows the recommendation for approval, LUMYKRAS will be the first targeted therapy available in the European Union (EU) for the KRAS G12C mutation, one of the most prevalent biomarkers in NSCLC. The CHMP based its positive opinion on results from the Phase 2 CodeBreaK 100 clinical trial, the largest trial conducted to date exclusively for patients with the KRAS G12C mutation. CodeBreaK 100 enrolled 126 patients, 124 of whom had centrally evaluable lesions at baseline. In the trial, LUMYKRAS demonstrated favorable efficacy and tolerability in these 124 patients with KRAS G12C mutation-positive NSCLC who had disease progression after receiving an immunotherapy and/or chemotherapy. LUMYKRAS 960 mg, administered orally once-daily, demonstrated an objective response rate (a proportion of patients with = 30% decrease in the sum of the longest diameter of the target lesions compared with baseline) of 37.1% (95% CI: 28.6-46.2) a median duration of response (DoR) of 11.1 months, disease control rate (DCR) of 80.6% and median overall survival (OS) of 12.5 months. The most common treatment-related adverse reactions were diarrhea (32%), nausea (19%), increase in aminotransferase level (ALT) and increase in the aspartate aminotransferase level (AST) (15% each). The most common severe (grade = 3) treatment-related adverse reactions were increased alanine aminotransferase (ALT; 6%), increased aspartate aminotransferase (AST; 6%), and diarrhea (4%). Only 7% of patients discontinued treatment due to treatment-related adverse events. NSCLC accounts for approximately 84% of the 2.2 million new lung cancer diagnoses each year worldwide, including approximately 400,000 new cases in Europe.4,5 KRAS G12C is one of the most prevalent driver mutations in NSCLC, with about 13-15% of patients with non-squamous NSCLC having the KRASG12C mutation.6,7 LUMYKRAS, which is administered orally in a tablet formulation, binds with the mutated KRAS G12C protein keeping the mutated protein in an inactive state, thus preventing it from switching to its favored active state that supports cancer cell growth. LUMYKRAS has been shown to irreversibly bind to the inactive KRAS G12C protein, permanently locking it in an inactive state, inhibiting oncogenic signaling and tumorigenesis.

Neutral

FRISQ Holding AB (publ) in Collaboration with UCB and Amgen to Facilitate the Implementation of Care Plans for Osteoporosis Patients

2021-11-11 10:15:00

FRISQ Holding AB (publ) has entered into an agreement with biotechnology companies UCB and Amgen, to collaborate with selected clinics to design comprehensive, digitalized care plans for patients suffering from osteoporosis. The project will be financed by UCB Pharma Sweden. The order value for FRISQ is approximately SEK 0.5 million, excluding any additional orders for implementation and license revenues that may be added for additional clinics that join. Belgium-based UCB and US-based Amgen, both companies in biopharmaceuticals, are already collaborating in the diagnostic field of osteoporosis. A new collaboration in Sweden is now being initiated with FRISQ with the ambition to contribute to improved outcomes and health of the patients by increasing their own involvement in their care and ensuring that the care provided is more patient centered. With help from the software solution FRISQ Care, comprehensive and digital care plans will be designed for patients in this area. The project starts in November and the first step is to select clinics that will participate in the project. Thereafter, FRISQ Care will be configured for participating clinics and patients. Osteoporosis is a therapy area with a big potential for achieving better outcomes by using more efficient systems for follow up. It’s a widespread disease that is also underdiagnosed – the risk of further fractures after a first osteoporosis-related fracture is very high. It also takes up a significant proportion of health care resources. Osteoporosis is strongly associated with a reduced quality of life, and it can lead to increased social isolation. According to Socialstyrelsen’s (National Board of Health and Welfare) guidelines, taking early measures and having a close collaboration between several care professions is required in order to be able to provide optimal care for this patient group. In that context, an effective care plan is absolutely crucial. The same document from Socialstyrelsen also warns that osteoporosis is a “low-status disease” that is treated differently in different parts of the country – there are large regional differences in the number of patients that get a new osteoporotic fracture after their first. All in all, these are strong indications that digital care plans and a person-centered approach can be of great benefit.

Neutral

Amgen Inc. Presents at Cowen’s 5th Annual IO Next Virtual Summit, Nov-15-2021 02:15 PM

2021-11-10 21:00:00

Amgen Inc. Presents at Cowen’s 5th Annual IO Next Virtual Summit, Nov-15-2021 02:15 PM. Speakers: David M. Reese, Executive Vice President of Research & Development.

Neutral

Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022

2021-11-09 17:12:00

Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022. Venue: San Diego Convention Center, San Diego, California, United States.

Neutral

Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022

2021-11-09 17:12:00

Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022. Venue: San Diego Convention Center, San Diego, California, United States.

Positive

Amgen Announces New Data from the HER-MES Study

2021-11-08 21:09:00

Amgen announced new data from the HER-MES study, the first and only head-to-head study of Aimovig® (erenumab-aooe), a calcitonin gene-related peptide (CGRP) inhibitor, against topiramate for adult patients with episodic and chronic migraine. Topiramate is one of the most commonly prescribed medications in migraine prevention with an estimated 600,000 new-to-brand prescriptions written in the U.S. each year. Published in Cephalalgia, the results of the study conducted by Novartis showed that patients in the Aimovig treatment arm experienced a significantly lower discontinuation rate due to adverse events and superior efficacy, with a greater proportion of patients achieving at least a 50% reduction from baseline in their monthly migraine days (MMDs), compared with topiramate. In this head-to-head Phase IV study, patients in the Aimovig arm demonstrated a significantly lower discontinuation rate due to adverse events versus patients in the topiramate arm (10.6% versus 38.9%). Additionally, significantly more patients in the Aimovig arm achieved at least a 50% reduction from baseline in their MMDs than those in the topiramate group (55.4% versus 31.2%). In the topiramate group, the most frequent adverse events that led to discontinuation of the study medication were paraesthesia, disturbance in attention, fatigue, and nausea. In the Aimovig group, these were fatigue, nausea, disturbance in attention and dizziness. Additional study treatment-related adverse events reported by =2% in any trial group included constipation, decreased appetite, taste disorder, vertigo, dysgeusia, weight loss, dry mouth, irritability, mood swings, diarrhea, depression, sleep disorder, depressed mood, hypoesthesia, upper abdominal pain, aphasia, insomnia, memory impairment, dyspepsia, dysesthesia and headache.

Neutral

Amgen Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-10-2021

2021-11-07 10:00:00

Amgen Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-10-2021 . Venue: Rancho Palos Verdes, California, United States. Speakers: Murdo Gordon, Executive VP of Global Commercial Operations, Peter H. Griffith, Executive VP & CFO.

Positive

Amgen Inc. Begins Construction on New Biomanufacturing Plant in Central Ohio

2021-11-05 20:00:00

Amgen Inc. announced the groundbreaking of its newest biomanufacturing plant, located in New Albany, Ohio. The final product assembly and packaging plant will support the growing demand for Amgen's medicines in the United States and is expected to be operational by 2024.

Neutral

Amgen Inc. Presents at BMO Biopharma Spotlight Series: Emerging Trends & Therapeutics in Oncology, Nov-08-2021 02:05 PM

2021-11-04 13:52:00

Amgen Inc. Presents at BMO Biopharma Spotlight Series: Emerging Trends & Therapeutics in Oncology, Nov-08-2021 02:05 PM. Speakers: David M. Reese, Executive Vice President of Research & Development.

Neutral

Amgen Inc. has filed a Shelf Registration in the amount of $42.852 million.

2021-11-03 00:00:00

Amgen Inc. has filed a Shelf Registration in the amount of $42.852 million. Security Name: Common Stock Securities Offered: 200,000 Transaction Features: ESOP Related Offering

Neutral

Amgen Inc. Provides Earnings Guidance for the Year 2021

2021-11-02 20:01:00

Amgen Inc. provided earnings guidance for the year 2021. For the full year 2021, the Company now expects: total revenues in the range of $25.8 billion to $26.2 billion. On a GAAP basis, EPS in the range of $9.55 to $10.21.

Neutral

Tranche Update on Amgen Inc. (NasdaqGS:AMGN)'s Equity Buyback Plan announced on April 21, 2011.

2021-11-02 16:28:00

From July 1, 2021 to September 30, 2021, the company has repurchased 4,638,964 shares, representing 0.81% for $1,068.96 million. With this, the company has completed the repurchase of 391,311,270 shares, representing 50.99% for $52,252.11 million under the buyback announced on April 21, 2011.

Neutral

BMO Capital Markets Corp., BMO Biopharma Spotlight Series: Emerging Trends & Therapeutics in Oncology, Nov 08, 2021

2021-11-01 12:00:00

BMO Capital Markets Corp., BMO Biopharma Spotlight Series: Emerging Trends & Therapeutics in Oncology, Nov 08, 2021.

Neutral

Amgen Inc. to Report Q3, 2021 Results on Nov 02, 2021

2021-10-28 20:00:00

Amgen Inc. announced that they will report Q3, 2021 results After-Market on Nov 02, 2021

Neutral

Informa plc, Competition Law in the Pharmaceutical Sector programme, Nov 05, 2021

2021-10-27 16:16:00

Informa plc, Competition Law in the Pharmaceutical Sector programme, Nov 05, 2021.

Neutral

Amgen Inc. Presents at Competition Law in the Pharmaceutical Sector programme, Nov-05-2021

2021-10-27 16:16:00

Amgen Inc. Presents at Competition Law in the Pharmaceutical Sector programme, Nov-05-2021 .

Neutral

Amgen Inc. Presents at BioData World Congress 2021, Nov-02-2021 through Nov-04-2021

2021-10-26 19:08:00

Amgen Inc. Presents at BioData World Congress 2021, Nov-02-2021 through Nov-04-2021. Presentation Date & Speakers: Nov-02-2021, Adrien Rousset, Head of Augmented Diagnostics & Patient Identification, Peter Grandsard, Executive Director Research. Nov-03-2021, Adam Zalewski, Senior Scientist, Adrien Rousset, Head of Augmented Diagnostics & Patient Identification.

Neutral

Cowen and Company, LLC, Cowen’s 5th Annual IO Next Virtual Summit, Nov 15, 2021

2021-10-25 20:58:00

Cowen and Company, LLC, Cowen’s 5th Annual IO Next Virtual Summit, Nov 15, 2021.

Positive

Amgen Inc. Declares Dividend for the Fourth Quarter of 2021, Payable on December 8, 2021

2021-10-21 20:00:00

Amgen Inc. announced that its Board of Directors declared a $1.76 per share dividend for the fourth quarter of 2021. The dividend will be paid on December 8, 2021, to all stockholders of record as of the close of business on November 16, 2021.

Positive

Amgen Inc., $ 1.76, Cash Dividend, Nov-15-2021

2021-10-21 00:00:00

Amgen Inc., $ 1.76, Cash Dividend, Nov-15-2021

Neutral

Amgen Inc. Presents at 4th Annual Targeted Protein Degradation Summit, Oct-27-2021 02:15 PM

2021-10-19 20:56:00

Amgen Inc. Presents at 4th Annual Targeted Protein Degradation Summit, Oct-27-2021 02:15 PM. Speakers: Ryan Potts, Head of Induced Proximity Platform.

Positive

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of TeneoBio, Inc. from Lightspeed Ventures, LLC and Sutter Hill Ventures.

2021-10-19 00:00:00

Amgen Inc. (NasdaqGS:AMGN) announced an agreement to acquire TeneoBio, Inc. from Lightspeed Venture Partners, Sutter Hill Ventures and others for $2.5 billion on July 27, 2021. The purchase price is subject to customary adjustments. Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to Teneobio equity holders potentially worth up to an additional $1.6 billion in cash. The acquisition is subject to customary closing conditions, including applicable regulatory approvals, antitrust approvals and Teneobio’s completion of certain restructuring arrangements with respect to its subsidiaries, including the spin out of three of Teneobio’s subsidiaries to the pre-closing equity holders of Teneobio and the closing of AbbVie Inc.’s acquisition of TeneoOne, Inc. The transaction is expected to close in the second half of 2021. Goldman Sachs & Co. LLC acted as financial advisor and Daniel Rees, Charles Ruck, Steve Chinowsky, Darryl Steensma, Eliot Choy, Michelle Carpenter, Larry Stein, William Kessler, Elizabeth Richards, Robert Blamires, Mandy Reeves and Patrick English of Latham & Watkins LLP acted as legal advisors to Amgen. Michael Irvine, Michael Richman, Steve Ray, Colin Chapman and Craig Olshan of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP acted as legal advisors to TeneoBio. Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of TeneoBio, Inc. from Lightspeed Ventures, LLC and Sutter Hill Ventures on October 19, 2021.

Neutral

Jasper Therapeutics, Inc. has filed a Shelf Registration in the amount of $277.553726 million.

2021-10-15 00:00:00

Jasper Therapeutics, Inc. has filed a Shelf Registration in the amount of $277.553726 million. Security Name: Common Stock Securities Offered: 33,081,493

Neutral

Hanson Wade Limited, 4th Annual Targeted Protein Degradation Summit, Oct 26, 2021 through Oct 29, 2021

2021-10-13 11:00:00

Hanson Wade Limited, 4th Annual Targeted Protein Degradation Summit, Oct 26, 2021 through Oct 29, 2021.

Neutral

Amgen Inc., Q3 2021 Earnings Call, Nov 02, 2021

2021-10-13 06:54:00

Amgen Inc., Q3 2021 Earnings Call, Nov 02, 2021

Positive

Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021

2021-10-07 13:00:00

Amgen announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of LUMAKRAS™ (sotorasib), the first and only approved KRASG12C inhibitor, in more than 10 different investigational combination regimens for the treatment of patients with KRAS G12C-mutated cancers. Results from two arms of the study — LUMAKRAS with afatinib, a pan-ErbB tyrosine kinase inhibitor, and LUMAKRAS with trametinib, a mitogen-activated protein kinase inhibitor (MEKi) — will be presented at the plenary session titled 'Drugging Difficult Targets' during the AACR-NCI-EORTC 2021 Virtual International Conference on Molecular Targets and Cancer Therapeutics on Saturday, Oct. 9, 2021. The LUMAKRAS and afatinib combination arm enrolled 33 heavily pre-treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), including five patients previously treated with LUMAKRAS monotherapy. Ten patients received 20 mg of afatinib/960 mg of sotorasib (cohort 1; 4 patients with prior LUMAKRAS experience) and 23 patients received 30 mg of afatinib/960 mg of sotorasib (cohort 2; 1 patient with prior LUMAKRAS experience). The objective response rate (ORR) was 20% in cohort 1 and 35% in cohort 2, and the disease control rate was 70% and 74% in the two cohorts, respectively. The most common treatment-related adverse events (TRAEs) for this study were diarrhea, nausea, and vomiting. TRAEs of grade 3 occurred in 30% of patients in both dose groups with diarrhea being the most common. In CodeBreaK 101, the combination of LUMAKRAS and trametinib showed antitumor activity in heavily pre-treated patients with KRAS G12C-mutated solid tumors, including those with prior KRASG12C inhibitor treatment. A total of 41 patients were enrolled in the Phase 1b study with 18 patients with NSCLC, 18 patients with colorectal cancer (CRC) and five patients with other solid tumors. The maximum tolerated dose tested was 2 mg trametinib/960 mg sotorasib administered daily. In patients with CRC who were KRASG12C inhibitor naïve, 9% achieved partial response (1 of 11), and 82% achieved disease control (9 of 11). In patients who were previously treated with a KRASG12C inhibitor, 14% achieved partial response (1 of 7), and 86% achieved disease control (6 of 7). In patients with NSCLC who were KRASG12C inhibitor naïve, 20% achieved partial response (3 of 15) and 87% achieved disease control (13 of 15). In patients who were previously treated with a KRASG12C inhibitor, 67% achieved disease control (2 of 3).

Positive

Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases

2021-10-07 10:30:00

Amgen Inc. and Neumora Therapeutics Inc. announced a strategic collaboration to advance neuroscience discovery, development and commercialization. The companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities. In addition, Neumora has received a $100 million equity investment from Amgen and acquired exclusive global rights to develop and commercialize Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases. Neumora leverages proprietary multimodal capabilities and technologies to integrate advanced computational data science with R&D to increase the probability of success of drug development in brain diseases. Neumora's precision neuroscience platform focuses on the creation of Data Biopsy Signatures™ to deconvolve the complex systems that drive brain diseases and connect the signatures to clinically meaningful measures to inform the development of therapeutics for an enriched patient population, or Precision Phenotypes™. Amgen's deCODE genetics subsidiary is a global leader in analyzing and understanding human health and disease and has been at the forefront of the analysis of human data to enhance drug discovery and development. By leveraging these platform technologies and the complementary capabilities of both companies, the collaboration aims to discover unique and unprecedented insights into brain diseases across neuropsychiatric and neurodegenerative diseases, including schizophrenia and amyotrophic lateral sclerosis (ALS), ultimately leading to effective therapeutics targeted at patients most likely to respond to treatment.

Positive

Neumora announced that it has received $500 million in funding from a group of investors

2021-10-07 00:00:00

Neumora announced that it has received $500 million in a round of funding led by Arch Venture Partners, L.P. on October 7, 2021. The company issued Common shares for gross proceeds of $100 million to new investor Amgen Inc. The transaction included participation from Alexandria Venture Investments, LLC, Altitude Life Science Ventures, Catalio Capital Management, LP, F Prime, Inc., The Invus Group, LLC, Logos Capital LLC, Mubadala Capital, Newpath Management, L.P., Polaris Partners L.P., reMind Capital Ltd., SoftBank Vision Fund 2, a fund managed by SoftBank Investment Advisers (UK) Limited, Citadel Multi-Strategy Equities Master Fund Ltd., a fund managed by Citadel Advisors LLC, Waycross Ventures and other undisclosed investors.

Neutral

Amgen Inc. Presents at DIA: Digital Technology in Clinical Trials conference, Oct-27-2021

2021-10-06 16:45:00

Amgen Inc. Presents at DIA: Digital Technology in Clinical Trials conference, Oct-27-2021 . Speakers: Alison Luckman, Development Operations Innovation Director, Megan Doyle, Global Policy Lead, Digital Health, Diagnostics, and Combination Products.

Neutral

Drug Information Association, Inc., DIA: Digital Technology in Clinical Trials conference, Oct 27, 2021 through Oct 29, 2021

2021-10-06 12:29:00

Drug Information Association, Inc., DIA: Digital Technology in Clinical Trials conference, Oct 27, 2021 through Oct 29, 2021.

Neutral

Terrapinn Holdings Ltd, BioData World Congress 2021, Nov 02, 2021 through Nov 04, 2021

2021-10-06 12:29:00

Terrapinn Holdings Ltd, BioData World Congress 2021, Nov 02, 2021 through Nov 04, 2021.

Neutral

Amgen Inc. Presents at AusBiotech 2021, Oct-27-2021 01:30 PM

2021-10-05 13:01:00

Amgen Inc. Presents at AusBiotech 2021, Oct-27-2021 01:30 PM. Speakers: Amanda Mason, Global Head of Search and Evaluation for Inflammation/Immunoscience, Business Development.

Neutral

AusBiotech Ltd., AusBiotech 2021, Oct 25, 2021 through Oct 29, 2021

2021-10-05 08:37:00

AusBiotech Ltd., AusBiotech 2021, Oct 25, 2021 through Oct 29, 2021.

Positive

Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress

2021-10-02 09:00:00

Kyowa Kirin Co., Ltd. and Amgen announced that positive data from a Phase 2 study of KHK4083/AMG 451 were presented at the European Academy of Dermatology and Venereology 30th Virtual Congress on Oct. 2, 2021. KHK4083/AMG 451 is a potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic dermatitis. The Phase 2, multicenter, randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of KHK4083 /AMG 451 in adults with moderate-to-severe atopic dermatitis who were not adequately controlled with topical agents. The study met the primary objective, showing statistically greater improvements from baseline in Eczema Area and Severity Index (EASI) score at 16 weeks with all four subcutaneous doses of KHK4083/AMG 451 compared with placebo (600 mg every two weeks (Q2W) = -57.4%*; 600 mg Q4W = -49.7%*; 300 mg Q2W = -61.1%*; 150 mg Q4W = -48.3%*; placebo = -15%). All treatment groups of patients treated with KHK4083/AMG 451 generally achieved improvements compared to placebo at week 16 for key secondary endpoints, such as achieving at least a 75% reduction from baseline in EASI score (EASI-75), an Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least 2-point reduction from baseline (IGA 0/1) and at least a 4-point reduction from baseline in pruritus Numerical Rating Scale (NRS) score (PNRS-4). Efficacy measures continued to improve after week 16 for all KHK4083/AMG 451 doses. The most commonly reported adverse events that occurred in at least 5% of patients were pyrexia, nasopharyngitis worsening of atopic dermatitis and chills. The events of pyrexia and chills were mild to moderate in intensity and did not lead to treatment discontinuations.

Neutral

BioFlorida, Inc., Brain Foundation, BioFlorida Conference, Dec 08, 2021 through Dec 10, 2021

2021-10-01 16:14:00

BioFlorida, Inc., Brain Foundation, BioFlorida Conference, Dec 08, 2021 through Dec 10, 2021. Venue: Renaissance Orlando at SeaWorld, 6677 Sea Harbor Dr, Orlando, Florida, United States.

Positive

Amgen Inc. announces an Increase in Equity Buyback.

2021-10-01 00:00:00

In October 2021, the company announced an increase in its equity buyback plan. The company increased its authorization by $4,500 million, thereby bringing the total authorization to $59,604.38 million.

Neutral

Amgen Inc. Presents at 30th European Academy of Dermatology and Venereology Congress, Sep-29-2021

2021-09-29 10:50:00

Amgen Inc. Presents at 30th European Academy of Dermatology and Venereology Congress, Sep-29-2021 .

Neutral

Amgen Inc. Presents at HealthTech Innovation Days 2021, Oct-05-2021 04:50 PM

2021-09-29 07:24:00

Amgen Inc. Presents at HealthTech Innovation Days 2021, Oct-05-2021 04:50 PM. Venue: Paris, France. Speakers: Isma Benattia, VP R&D Strategy & Business Operations.

Neutral

Amgen Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 through Oct-05-2021

2021-09-28 18:44:00

Amgen Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 through Oct-05-2021. Presentation Date & Speakers: Oct-04-2021, Raymond J. Deshaies, Senior Vice President of Global Research. Oct-05-2021, David M. Reese, Executive Vice President of Research & Development.

Neutral

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Neutral

Amgen Inc. Presents at Heartland Summit, Sep-30-2021 08:00 AM

2021-09-27 03:33:00

Amgen Inc. Presents at Heartland Summit, Sep-30-2021 08:00 AM. Venue: Minnepolis, Minnesota, United States. Speakers: Robert A. Bradway, Chairman, CEO & President.

Positive

Amgen Announces U.S. Food and Drug Administration Approves Repatha in Pediatric Patients Age 10 and Older with Heterozygous Familial Hypercholesterolemia

2021-09-25 00:09:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C. HeFH is an inherited, genetic condition with a prevalence of one in 250 people worldwide. High levels of LDL-C starting at birth accelerate the development of atherosclerotic cardiovascular disease, leading to an overall increased risk of cardiovascular events, including heart attack and other vascular conditions, at an earlier age. Children with familial hypercholesterolemia (FH) can be normal weight, have a good diet, exercise enough and still have high LDL-C. The approval is based on the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha in pediatric patients, 10 - 17 years of age, with HeFH. Monthly treatment with Repatha reduced LDL-C by mean 38% (95% CI: 45%, 31%; p < 0.0001) from baseline compared to placebo, meeting its primary endpoint.4 Reductions in LDL-C were observed by the first post-baseline assessment at the Week 12 time point and were maintained throughout the trial. Patients treated with Repatha had improved secondary lipid parameters from baseline in comparison to placebo, including a 35% (CI: 42%, 28%) reduction in non-high-density lipoprotein cholesterol (non-HDL-C) at week 24, a 27% (CI: 32%, 21%) reduction in total cholesterol at week 24 and a 32% (CI: 39%, 26%) reduction in apolipoprotein B (ApoB) at week 24.5 No new safety risks were identified. The most common treatment-emergent adverse events (>5% of patients treated with Repatha and occurring more frequently than placebo) included nasopharyngitis, headache, oropharyngeal pain, influenza and upper respiratory tract infection.The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients. Repatha was already approved for treatment in HoFH patients aged 13 and older and is now available as a treatment for patients aged 10 and older.

Positive

Amplitude Healthcare Acquisition Corporation announced that it has received $100 million in funding from a group of investors

2021-09-24 00:00:00

On September 24, 2021, Jasper Therapeutics, Inc. closed the transaction.

Neutral

Amgen Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 02:00 PM

2021-09-22 20:00:00

Amgen Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 02:00 PM. Venue: New York, United States. Speakers: Peter H. Griffith, Executive VP & CFO, Susan Sweeney, Senior Vice President of Global Marketing, Access & Capabilities.

Neutral

Amgen Inc. Presents at Festival of Biologics Basel 2021, Nov-10-2021 03:00 PM

2021-09-22 15:38:00

Amgen Inc. Presents at Festival of Biologics Basel 2021, Nov-10-2021 03:00 PM. Venue: Congress Centre, Basel, Switzerland. Speakers: María Lucía Bettati, Business Unit Director Gen Med.

Neutral

Amgen Inc. Presents at Ninth Annual C-Suite Summit, Oct-15-2021

2021-09-21 13:00:00

Amgen Inc. Presents at Ninth Annual C-Suite Summit, Oct-15-2021 . Speakers: Elliott Levy, Head, Intrepid Alliance.

Neutral

European Academy Of Dermatology And Venereology, 30th European Academy of Dermatology and Venereology Congress, Sep 29, 2021 through Oct 02, 2021

2021-09-20 12:00:00

European Academy Of Dermatology And Venereology, 30th European Academy of Dermatology and Venereology Congress, Sep 29, 2021 through Oct 02, 2021.

Positive

Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer

2021-09-20 11:00:00

Verastem Oncology announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766, Verastem Oncology’s investigational dual RAF/MEK inhibitor, with Amgen’s KRAS G12C inhibitor LUMAKRASTM (sotorasib) in KRAS G12C-mutant non-small cell lung cancer (NSCLC). The Phase 1/2 trial will evaluate the safety, tolerability and efficacy of VS-6766 in combination with LUMAKRASTM in patients with KRAS G12C-mutant NSCLC who have not been previously treated with a KRAS G12C inhibitor as well as in patients who have progressed on a KRAS G12C inhibitor. The study will therefore investigate the potential benefits of a more complete vertical blockade of the RAS pathway with the combination of VS-6766 (RAF/MEK blockade) with LUMAKRASTM (G12C inhibition) in KRAS G12C-mutant locally advanced or metastatic NSCLC. Verastem Oncology expects to initiate the clinical trial with VS-6766 and LUMAKRASTM by the end of 2021.

Neutral

Amgen Inc. Presents at Indegene Digital Summit, Sep-24-2021 09:30 AM

2021-09-16 17:31:00

Amgen Inc. Presents at Indegene Digital Summit, Sep-24-2021 09:30 AM. Speakers: Nerissa Gomes, Director, Marketing & Lifecycle Management (Inflammation).

Neutral

Amgen Inc. Presents at 3rd Annual RAS Targeted Drug Development Summit, Sep-21-2021 through Sep-23-2021

2021-09-16 13:29:00

Amgen Inc. Presents at 3rd Annual RAS Targeted Drug Development Summit, Sep-21-2021 through Sep-23-2021. Presentation Date & Speakers: Sep-22-2021, Gregory Friberg, Head of Oncology Global Development.

Positive

Amgen Inc. Announces the First Combination Study Results from the Phase 1B/2 Codebreak 101 Study

2021-09-16 08:30:00

Amgen Inc. announced the first combination study results from the Phase 1b/2 CodeBreaK 101 study, the most comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer (CRC). These new data show that combining LUMAKRAS (sotorasib) with Vectibix (panitumumab), Amgen's monoclonal antibody epidermal growth factor receptor (EGFR) inhibitor, demonstrated encouraging efficacy and safety. Overall, the objective response rate (ORR) was 27% (confirmed and unconfirmed) among 26 patients in the efficacy analysis set (which included 5 patients who had progressed with prior sotorasib monotherapy). The disease control rate (DCR) was 81%. ORR and DCR were secondary endpoints. In the expansion cohort of sotorasib-naïve patients with refractory CRC (n=18), 33% of patients experienced a response (confirmed and unconfirmed). These data are being featured during the European Society of Medical Oncology 2021 (ESMO21) Virtual Congress. In total, 31 patients with heavily pretreated (median of two prior lines of therapy; range 1-10) KRAS G12C-mutated metastatic CRC were enrolled in the dose exploration and dose expansion cohorts for the combination of LUMAKRAS and Vectibix. No patients experienced dose-limiting toxicities during the 28 days following initial treatment. The majority of treatment-related adverse events (TRAEs) were Grade 1-2 in severity, and no Grade 4 or fatal TRAEs were observed. The most common TRAEs (occurring in > 10% of patients) were consistent with known adverse events for LUMAKRAS and Vectibix and included dermatitis acneiform, dry skin, nausea, diarrhea, hypokalemia, hypomagnesemia, pruritus and rash. No new safety concerns were identified. In addition to the LUMAKRAS combination research, a presentation will detail the design of an ongoing study of half-life extended (HLE) bispecific T cell engager (BiTE®) molecule tarlatamab with anti-PD-1 antibody AMG 404 in patients with small cell lung cancer. The multicenter, open-label, Phase 1b study will evaluate the safety and tolerability of the combination and determine dosing as primary objectives, as well as examine preliminary antitumor activity and pharmacokinetics as secondary objectives.

Neutral

Indegene, Inc., Indegene Digital Summit, Sep 23, 2021 through Sep 24, 2021

2021-09-15 12:30:00

Indegene, Inc., Indegene Digital Summit, Sep 23, 2021 through Sep 24, 2021.

Positive

Health Canada Approves Amgen's LUMAKRAS™ (Sotorasib), the First and Only Targeted Treatment for Patients with KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

2021-09-14 11:00:00

Amgen announced that Health Canada has approved LUMAKRASTM (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. LUMAKRAS was granted a Notice of Compliance with Conditions (NOC/c) based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Health Canada based its approval of LUMAKRAS on results from a subset of patients in the phase 2 CodeBreaK 100trial, the largest clinical trial conducted to date exclusively for patients with the KRAS G12C mutation. The trial investigated efficacy and tolerability in 126 patients with KRAS G12C mutation-positive advanced NSCLC who had disease progression after receiving an immunotherapy and/or chemotherapy. The most common adverse reactions (20%) were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity and cough. Adverse reactions resulting in permanent discontinuation of LUMAKRAS occurred in 9% of patients.

Neutral

Amgen Inc. Presents at Bank of America Global Healthcare Conference, Sep-17-2021 11:45 AM

2021-09-13 20:15:00

Amgen Inc. Presents at Bank of America Global Healthcare Conference, Sep-17-2021 11:45 AM. Speakers: Peter H. Griffith, Executive VP & CFO.

Neutral

Amgen Inc. - Special Call

2021-09-13 20:03:00

To discuss clinical data being presented on the Company's KRASG12C inhibitor LUMAKRAS(TM) (sotorasib) in combination with Vectibix(R) (panitumumab)

Neutral

Amgen Inc. - Special Call

2021-09-13 13:00:00

To discuss clinical data being presented at EADV, including data from the AMG 451/KHK4083 Phase 2 trial in patients with moderate-to-severe atopic dermatitis, as well as the broader inflammation portfolio

Neutral

EIT Health e.V., HealthTech Innovation Days 2021, Oct 04, 2021 through Oct 05, 2021

2021-09-13 06:00:00

EIT Health e.V., HealthTech Innovation Days 2021, Oct 04, 2021 through Oct 05, 2021. Venue: Paris, France.

Neutral

Amgen Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 02:45 PM

2021-09-09 21:00:00

Amgen Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 02:45 PM. Venue: New Windsor, United States. Speakers: Robert A. Bradway, Chairman, CEO & President.

Positive

Amgen Announces Results from Two Analyses of the Phase 2 CodeBreaK 100 Clinical Trial Evaluating LUMAKRAS™

2021-09-08 20:00:00

Amgen announced results from two analyses of the Phase 2 CodeBreaK 100 clinical trial evaluating LUMAKRAS™ (sotorasib), the first and only KRASG12C inhibitor approved in the U.S., in the treatment of previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). These new analyses, respectively, provide encouraging evidence of durable systemic anticancer activity in patients with previously treated, stable brain metastases with LUMAKRAS, as well as insights into biomarkers of LUMAKRAS response. Together with a poster describing a recently initiated clinical study of the investigational half-life extended (HLE) bispecific T cell engager (BiTE®) molecule acapatamab (formerly AMG 160) in patients with NSCLC, these data are being featured during the virtual 2021 World Conference on Lung Cancer (WCLC21) hosted by the International Association for the Study of Lung Cancer (IASLC). In a post-hoc analysis (WCLC21 Poster 52.03) of 40 patients (23% of 174 trial participants) with KRAS G12C-mutated advanced NSCLC who had stable, previously treated brain metastases at their enrollment in the CodeBreaK 100 trial, LUMAKRAS achieved a 77.5% disease control rate (DCR), a median progression-free survival (PFS) of 5.3 months and a median overall survival (OS) of 8.3 months. This DCR was similar to patients without brain metastases. In patients evaluable by Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, 14 of 16 patients (88%) maintained intracranial disease control of their stable brain lesions during LUMAKRAS therapy with two achieving complete responses of non-target lesions. The safety profile of LUMAKRAS in the brain metastases group was consistent with previous reports. Amgen is enrolling patients with active brain metastases in an arm of the CodeBreaK 101 study (NCT04185883). An additional exploratory descriptive analysis of CodeBreaK 100 being presented during a Mini Oral Presentation (MA14.03) examined whether the mutation profile of the tumors, in addition to KRASG12C, is correlated with patients' responses or resistance to LUMAKRAS. An analysis of baseline tumor samples from 65 patients revealed no single genetic signature that predicted LUMAKRAS responses and ongoing evaluations will be needed to further identify potential targetable mechanisms of resistance. However, the KEAP1 mutation, a known driver of poor clinical outcomes, was observed in 7 of 22 patients with early progression and PFS of less than 3 months.

Positive

Amgen Announces New Data from the Pivotal Navigator Phase 3 Trial

2021-09-05 11:15:00

Amgen announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps. Tezepelumab is a potential first-in-class treatment that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine, and has the potential to treat a broad population of patients with severe asthma.2,3 Tezepelumab is being developed by Amgen in collaboration with AstraZeneca. The pre-specified exploratory analysis evaluated the effect of tezepelumab in NAVIGATOR patients with or without reported nasal polyps (NP+ or NP-) in the past two years. The analysis showed tezepelumab achieved an 86% reduction in the annualized asthma exacerbation rate (AAER) in NP+ patients (95% CI: 70, 93) and 52% (95% CI: 42, 61) in NP- patients over 52 weeks, compared to placebo when added to standard of care (SoC). Tezepelumab improved lung function at week 52 in both groups of patients with an increase in pre-bronchodilator forced expiratory volume in one second (FEV1) of 0.20 L (95% CI: 0.02, 0.37) and 0.13 L (95% CI: 0.08, 0.18) versus placebo in NP+ and NP- patients, respectively.1 Tezepelumab also achieved a clinically relevant improvement in nasal polyp symptoms at week 52, as measured by the Sinonasal Outcome Test (SNOT-22), reducing the SNOT-22 score in NP+ patients by 9.6 points (95% CI: 0.9, 18.2) versus placebo.1,4 The adjusted mean score reductions from baseline for tezepelumab and placebo were 20.10 points (SE: 3.07) and 10.55 points (SE: 2.94). Baseline mean (sd) SNOT-22 score was 49.4 (21.5) and 47.8 (19.0) for tezepelumab and placebo, respectively. These findings were presented at the European Respiratory Society (ERS) International Congress 2021 between September 5-8. There were no clinically meaningful differences in safety results between the tezepelumab and placebo groups in the NAVIGATOR trial. The most frequently reported adverse events with tezepelumab were nasopharyngitis, upper respiratory tract infection and headache.

Neutral

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022

2021-09-04 12:00:00

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022. Venue: Orlanda, Florida, United States.

Neutral

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun 21, 2022 through Jun 22, 2022

2021-09-04 07:34:00

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun 21, 2022 through Jun 22, 2022. Venue: Boston, United States.

Neutral

I.I.R Ltd., Competition Law in the Pharmaceutical Sector Conference, Dec 02, 2021

2021-09-03 12:40:00

I.I.R Ltd., Competition Law in the Pharmaceutical Sector Conference, Dec 02, 2021. Venue: Le Châtelain Boutique Hôtel, Brussels, Belgium.

Neutral

Amgen Inc. Presents at Competition Law in the Pharmaceutical Sector Conference, Dec-02-2021 11:05 AM

2021-09-03 12:40:00

Amgen Inc. Presents at Competition Law in the Pharmaceutical Sector Conference, Dec-02-2021 11:05 AM. Venue: Le Châtelain Boutique Hôtel, Brussels, Belgium. Speakers: Nicolas Pourbaix, Senior Counsel.

Neutral

Amgen Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 01:25 PM

2021-09-01 18:36:00

Amgen Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 01:25 PM. Venue: New York, United States. Speakers: Murdo Gordon, Executive VP of Global Commercial Operations.

Positive

Amgen Inc. Announces New Data at ESC Congress 2021 Shows Repatha (Evolocumab) Improves Features of Plaque Stability in Patients with Acute Coronary Syndrome

2021-08-27 08:30:00

Amgen announced positive data from the HUYGENS Phase 3 study showing that Repatha (evolocumab) in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features of plaque stability in patients with coronary artery disease (CAD). These data are being presented during an oral presentation at ESC Congress 2021, organized by the European Society of Cardiology, Aug. 27-30, 2021. Heart attacks are often the result of vulnerable plaque ruptures. Key features of vulnerable plaques are a large lipid core with a thin fibrous cap that serves as a wall or barrier around the plaque to keep it intact. The HUYGENS study assessed whether Repatha, in addition to optimized statin therapy, could increase the thickness of the fibrous caps, to ultimately improve a feature of plaque stability. The HUYGENS study met its primary endpoint, with Repatha in addition to optimized statin therapy increasing fibrous cap thickness by 42.7 um in comparison with an increase of 21.5 um (75% increase versus 39%) on optimized statin therapy alone (p=0.01), as measured by optical coherence tomography (OCT). Thus, the addition of Repatha improved this feature twice as well as statins alone. Repatha also improved all of the study's secondary endpoints, including decreasing the maximum lipid arc by -57.5° versus -31.4° (p=0.01), as measured by OCT. Results from the randomized, double-blind 52-week study in ACS patients on optimized statin therapy demonstrate that Repatha treatment, initiated within a week after the ACS event, reduced LDL-C from 140 to 28 mg/dL (-80%) versus reductions from 142 to 87 mg/dL (-39%) with statin optimization alone. No new safety risks were identified. The most common treatment-emergent adverse events (>3%) were angina pectoris, myalgia, hypertension, diarrhea, fatigue and cough. While HUYGENS did not evaluate cardiovascular outcomes, the results build on the growing body of evidence already supporting the clinical profile of Repatha. The HUYGENS study results add relevant insights to the science of plaque biology and contribute to its understanding of the important benefits of initiating Repatha after a heart attack. Fifty clinical trials, conducted with over 47,000 patients randomized to Repatha or placebo, have demonstrated the clinical benefits of Repatha, which include reduction in myocardial infarction and stroke, rapid (within four weeks) and dramatic LDL-C lowering over the long term (median 2.2 years), and consistent safety over a five-year treatment period generally consistent with the FOURIER study. Previous studies include GLAGOV which showed Repatha, when added to optimal statin therapy, reduced plaque burden by decreasing plaque atheroma volume in patients with CAD. This was the first study to demonstrate that lowering LDL-C levels through PCSK9 inhibition reduces atherosclerotic plaque burden. HUYGENS demonstrated that Repatha in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved a key feature of plaque stability in patients with CAD by increasing the fibrous cap thickness. HUYGENS may offer mechanistic insight for the CV event reduction seen in the FOURIER outcomes study.

Neutral

Amgen Inc. Presents at 6th Annual CAR-TCR Summit, Aug-30-2021 09:30 AM

2021-08-27 01:42:00

Amgen Inc. Presents at 6th Annual CAR-TCR Summit, Aug-30-2021 09:30 AM. Venue: Hynes Convention Center, Boston, Massachusetts, United States. Speakers: Faraz Zaman, Director & Lead - Global Medical.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Amgen Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021

2021-08-23 12:06:00

Amgen Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 . Venue: Paris Expo Porte de Versailles, Paris, France.

Neutral

Amgen Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 through Dec-02-2021

2021-08-18 15:33:00

Amgen Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 through Dec-02-2021. Venue: Loews Coronado Bay Resort, San Diego, California, United States. Presentation Date & Speakers: Dec-02-2021, Deepali Sawant, Senior Scientist. Nov-30-2021, Keegan Cooke, Senior Scientist, Oncology.

Positive

Amgen Inc. Issues and Sale $1,250,000,000 Aggregate Principal Amount of its 1.650% Senior Notes Due 2028

2021-08-09 20:07:00

On August 9, 2021, Amgen Inc. issued and sold $1,250,000,000 aggregate principal amount of its 1.650% Senior Notes due 2028 (the “2028 Notes”), $1,250,000,000 aggregate principal amount of its 2.000% Senior Notes due 2032 (the “2032 Notes”), $1,150,000,000 aggregate principal amount of its 2.800% Senior Notes due 2041 (the “2041 Notes”) and $1,350,000,000 aggregate principal amount of 3.000% Senior Notes due 2052 (the “2052 Notes” and, together with the 2028 Notes, the 2032 Notes and the 2041 Notes, the “Notes”). The Notes are registered under an effective Registration Statement on Form S-3 (Registration No. 333-236351) (the “Registration Statement”), filed on February 10, 2020, and were issued pursuant to an indenture, dated as of May 22, 2014 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, and an officer’s certificate, dated as of August 9, 2021 (the “Officer’s Certificate”), setting forth the terms of the Notes. Net proceeds to the Company from the offering were approximately $4,942,167,000, after deducting underwriters’ discounts and estimated offering expenses payable by the Company. The 2028 Notes will pay interest at the rate of 1.650% per annum, the 2032 Notes will pay interest at the rate of 2.000% per annum, the 2041 Notes will pay interest at the rate of 2.800% per annum and the 2052 Notes will pay interest at the rate of 3.000% per annum, which, in the case of the 2028 notes and the 2041 notes, shall be payable in cash semi-annually in arrears on February 15 and August 15 of each year, beginning on February 15, 2022, and in the case of the 2032 notes and the 2052 notes, shall be payable in cash semi-annually in arrears on January 15 and August 15 of each year, beginning on January 15, 2022. The 2028 Notes will mature on August 15, 2028, the 2032 Notes will mature on January 15, 2032, the 2041 Notes will mature on August 15, 2041 and the 2052 Notes will mature on January 15, 2052. In the event of a change in control triggering event, as defined in the Officer’s Certificate, the holders of the Notes may require the Company to purchase for cash all or a portion of their Notes at a purchase price equal to 101% of the principal amount of Notes, plus accrued and unpaid interest, if any. The descriptions of the Indenture, the Officer’s Certificate and the Notes in this report are summaries and are qualified in their entirety by the terms of the Indenture, the Officer’s Certificate and the Notes, respectively. The Notes will rank equal in right of payment to all of the Company’s other existing and future senior unsecured indebtedness, senior in right of payment to all of the Company’s existing and future subordinated indebtedness, effectively subordinated in right of payment to all of the Company’s subsidiaries’ obligations (including secured and unsecured obligations) and subordinated in right of payment to the Company’s secured obligations, to the extent of the assets securing such obligations.

Neutral

Amgen Inc. Presents at MD&M West conference, Aug-10-2021

2021-08-07 01:49:00

Amgen Inc. Presents at MD&M West conference, Aug-10-2021 . Venue: Anaheim Convention Cente, Anahiem, California, United States. Speakers: Bano Khaudeja, Executive Medical Director, Combination Product Safety Head.

Neutral

Amgen Inc. Presents at ATX West 2021, Aug-10-2021

2021-08-07 01:17:00

Amgen Inc. Presents at ATX West 2021, Aug-10-2021 . Venue: Anahiem, California, United States. Speakers: Khaudeja Bano, Executive Medical Director, Combination Product Safety Head.

Neutral

Amgen Inc. Presents at Reuters Total Health Virtual Global Conference, Nov-18-2021 12:15 PM

2021-08-05 10:39:00

Amgen Inc. Presents at Reuters Total Health Virtual Global Conference, Nov-18-2021 12:15 PM. Speakers: Robert A. Bradway, Chairman, CEO & President.

Neutral

Amgen Inc. Presents at Pharma & Patient USA, Nov-03-2021 11:00 AM

2021-08-05 08:52:00

Amgen Inc. Presents at Pharma & Patient USA, Nov-03-2021 11:00 AM. Speakers: Samantha Reyes, Patient Engagement Lead, Senior Manager.

Neutral

Amgen Inc. Presents at Pharma Europe, Oct-18-2021 10:15 AM

2021-08-05 08:20:00

Amgen Inc. Presents at Pharma Europe, Oct-18-2021 10:15 AM. Speakers: Chris Mann, Head of Commercial Excellence, UK & Ireland.

Neutral

Reuters Events, Pharma Europe, Oct 11, 2021 through Oct 22, 2021

2021-08-05 03:58:00

Reuters Events, Pharma Europe, Oct 11, 2021 through Oct 22, 2021.

Neutral

Reuters Events, Pharma & Patient USA, Nov 02, 2021 through Nov 04, 2021

2021-08-05 03:58:00

Reuters Events, Pharma & Patient USA, Nov 02, 2021 through Nov 04, 2021.

Neutral

Reuters Events, Reuters Total Health Virtual Global Conference, Nov 15, 2021 through Nov 18, 2021

2021-08-05 03:58:00

Reuters Events, Reuters Total Health Virtual Global Conference, Nov 15, 2021 through Nov 18, 2021.

Positive

Amgen Inc. has announced a Fixed-Income Offering.

2021-08-05 00:00:00

Amgen Inc. has announced a Fixed-Income Offering. Security Name: Fixed Rate Senior Subordinated Unsecured Notes due 2028 Security Type: Corporate Bond/Note (Non Convertible) Security Features: Callable Coupon Type: Fixed

Positive

Amgen Inc. has announced a Fixed-Income Offering.

2021-08-05 00:00:00

Amgen Inc. has announced a Fixed-Income Offering. Security Name: Fixed Rate Senior Subordinated Unsecured Notes due 2032 Security Type: Corporate Bond/Note (Non Convertible) Security Features: Callable Coupon Type: Fixed

Positive

Amgen Inc. has announced a Fixed-Income Offering.

2021-08-05 00:00:00

Amgen Inc. has announced a Fixed-Income Offering. Security Name: Fixed Rate Senior Subordinated Unsecured Notes due 2041 Security Type: Corporate Bond/Note (Non Convertible) Security Features: Callable Coupon Type: Fixed

Positive

Amgen Inc. has announced a Fixed-Income Offering.

2021-08-05 00:00:00

Amgen Inc. has announced a Fixed-Income Offering. Security Name: Fixed Rate Senior Subordinated Unsecured Notes due 2052 Security Type: Corporate Bond/Note (Non Convertible) Security Features: Callable Coupon Type: Fixed

Negative

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

2021-08-05 00:00:00

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

Negative

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

2021-08-05 00:00:00

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

Negative

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

2021-08-05 00:00:00

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

Negative

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

2021-08-05 00:00:00

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.341738 billion Fixed-Income Offering.

Positive

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.341738 billion.

2021-08-05 00:00:00

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.341738 billion. Security Name: 3% Senior Subordinated Unsecured Notes due January 15, 2052 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: $1.35 billion Price\Range: 99.388% Discount Per Security: 0.875% Security Features: Callable Coupon Type: Fixed

Negative

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

2021-08-05 00:00:00

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

Negative

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

2021-08-05 00:00:00

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

Negative

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

2021-08-05 00:00:00

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

Negative

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

2021-08-05 00:00:00

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.146493 billion Fixed-Income Offering.

Positive

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.146493 billion.

2021-08-05 00:00:00

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.146493 billion. Security Name: 2.800% Senior Subordinated Unsecured Notes due August 15, 2041 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: $1.15 billion Price\Range: 99.695% Discount Per Security: 0.75% Security Features: Callable Coupon Type: Fixed

Negative

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

2021-08-05 00:00:00

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

Negative

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

2021-08-05 00:00:00

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

Negative

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

2021-08-05 00:00:00

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

Negative

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

2021-08-05 00:00:00

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.2416 billion Fixed-Income Offering.

Positive

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.2416 billion.

2021-08-05 00:00:00

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.2416 billion. Security Name: 2% Senior Subordinated Unsecured Notes due January 15, 2032 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: $1.25 billion Price\Range: 99.328% Discount Per Security: 0.45% Security Features: Callable Coupon Type: Fixed

Negative

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

2021-08-05 00:00:00

Deutsche Bank Securities Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

Negative

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

2021-08-05 00:00:00

HSBC Securities (USA) Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

Negative

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

2021-08-05 00:00:00

J.P. Morgan Securities LLC has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

Negative

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

2021-08-05 00:00:00

MUFG Securities Americas Inc. has been added as the Co-Lead Underwriter for Amgen Inc.'s $1.24885 billion Fixed-Income Offering.

Positive

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.24885 billion.

2021-08-05 00:00:00

Amgen Inc. has completed a Fixed-Income Offering in the amount of $1.24885 billion. Security Name: 1% Senior Subordinated Unsecured Notes due August 15, 2028 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: $1.25 billion Price\Range: 99.908% Discount Per Security: 0.4% Security Features: Callable Coupon Type: Fixed

Neutral

Tranche Update on Amgen Inc. (NasdaqGS:AMGN)'s Equity Buyback Plan announced on April 21, 2011.

2021-08-04 10:11:00

From April 1, 2021 to June 30, 2021, the company has repurchased 6,518,985 shares, representing 1.13% for $1,591.94 million. With this, the company has completed the repurchase of 386,672,306 shares, representing 50.17% for $51,183.15 million under the buyback announced on April 21, 2011.

Negative

Amgen Inc. Revises Earnings Guidance for the Full Year 2021

2021-08-03 20:01:00

Amgen Inc. revised earnings guidance for the full year 2021. For the period, the company's EPS in the range of $8.84 to $9.90. Previously, the Company expected GAAP EPS in the range of $9.11 to $10.71. Total revenues in the range of $25.8 billion to $26.6 billion, unchanged from previous guidance.

Positive

Amgen Declares Dividend for the Third Quarter of 2021, Payable on September 8, 2021

2021-07-30 20:00:00

Amgen announced that its Board of Directors declared a $1.76 per share dividend for the third quarter of 2021. The dividend will be paid on September 8, 2021, to all stockholders of record as of the close of business on August 17, 2021.

Neutral

Amgen Inc. to Report Q2, 2021 Results on Aug 03, 2021

2021-07-30 00:00:00

Amgen Inc. announced that they will report Q2, 2021 results After-Market on Aug 03, 2021

Positive

Amgen Inc., $ 1.76, Cash Dividend, Aug-16-2021

2021-07-30 00:00:00

Amgen Inc., $ 1.76, Cash Dividend, Aug-16-2021

Neutral

Amgen Inc. Presents at Annual User Conference Cvent CONNECT, Aug-03-2021 08:00 AM

2021-07-29 23:46:00

Amgen Inc. Presents at Annual User Conference Cvent CONNECT, Aug-03-2021 08:00 AM. Speakers: Toby Frowen, Global Meetings Management Lead.

Negative

Amgen Announces Appointment of S. Omar Ishrak to its Board of Directors

2021-07-29 23:10:00

Amgen announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Compensation and Management Development Committee, effective July 30, 2021.Dr. Ishrak served as chairman and chief executive officer of Medtronic plc, a global medical technology company, from 2011 to 2020. During his tenure, Medtronic launched numerous innovative products, expanded geographically, completed several strategic acquisitions, and strengthened its commitment to social responsibility. Prior to joining Medtronic, Dr. Ishrak held numerous leadership positions at GE Healthcare, serving as president and chief executive officer of GE Healthcare Systems, GE Healthcare Clinical Systems, and GE Healthcare Ultrasound in his more than 15 years with the company. Dr. Ishrak has been a director of Intel Corporation since 2017 and was named chairman of the board in January 2020. Dr. Ishrak has served as chairman of the board of Compute Health Acquisition Corporation, a special purpose acquisition company, since January 2021. Dr. Ishrak also serves on the Board of Directors of the Cleveland Clinic and is a member of the Board of Trustees of the Asia Society, an educational organization dedicated to promoting mutual understanding and strong partnerships between Asia and the U.S. Since May 2021, Dr. Ishrak has been a senior advisor to Blackstone Life Sciences, a segment of the Blackstone Group Inc. that invests in the biopharmaceutical and medical technology industries to advance new treatments for patients.

Neutral

Informa plc, MD&M West conference, Aug 10, 2021 through Aug 12, 2021

2021-07-28 14:00:00

Informa plc, MD&M West conference, Aug 10, 2021 through Aug 12, 2021. Venue: Anaheim Convention Cente, Anahiem, California, United States.

Positive

Amgen Inc. (NasdaqGS:AMGN) announced an agreement to acquire TeneoBio, Inc. from Lightspeed Venture Partners, Sutter Hill Ventures and others for $2.5 billion.

2021-07-27 00:00:00

Amgen Inc. (NasdaqGS:AMGN) announced an agreement to acquire TeneoBio, Inc. from Lightspeed Venture Partners, Sutter Hill Ventures and others for $2.5 billion on July 27, 2021. The purchase price is subject to customary adjustments. Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to Teneobio equity holders potentially worth up to an additional $1.6 billion in cash. The acquisition is subject to customary closing conditions, including applicable regulatory approvals, antitrust approvals and Teneobio’s completion of certain restructuring arrangements with respect to its subsidiaries, including the spin out of three of Teneobio’s subsidiaries to the pre-closing equity holders of Teneobio and the closing of AbbVie Inc.’s acquisition of TeneoOne, Inc. The transaction is expected to close in the second half of 2021. Goldman Sachs & Co. LLC acted as financial advisor and Daniel Rees, Charles Ruck, Steve Chinowsky, Darryl Steensma, Eliot Choy, Michelle Carpenter, Larry Stein, William Kessler, Elizabeth Richards, Robert Blamires, Mandy Reeves and Patrick English of Latham & Watkins LLP acted as legal advisors to Amgen. Michael Irvine, Michael Richman, Steve Ray, Colin Chapman and Craig Olshan of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP acted as legal advisors to TeneoBio.

Neutral

Amgen Inc. Presents at KMWorld 2021, Nov-15-2021

2021-07-22 16:50:00

Amgen Inc. Presents at KMWorld 2021, Nov-15-2021 . Venue: JW Marriott, Washington, District Of Columbia, United States. Speakers: Brian McBreen, Director, Knowledge Analytics.

Neutral

Information Today, Inc., KMWorld 2021, Nov 15, 2021 through Nov 18, 2021

2021-07-22 14:53:00

Information Today, Inc., KMWorld 2021, Nov 15, 2021 through Nov 18, 2021. Venue: JW Marriott, Washington, District Of Columbia, United States.

Neutral

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021

2021-07-22 01:45:00

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay Resort, San Diego, California, United States.

Neutral

Informa plc, EU Merger Control 2021, Sep 28, 2021

2021-07-20 00:00:00

Informa plc, EU Merger Control 2021, Sep 28, 2021.

Neutral

Amgen Inc. Presents at EU Merger Control 2021, Sep-28-2021 10:50 AM

2021-07-20 00:00:00

Amgen Inc. Presents at EU Merger Control 2021, Sep-28-2021 10:50 AM. Speakers: Nicolas Pourbaix, Senior Counsel.

Neutral

Amgen Inc. Presents at Cambridge Health Institute PEGS Virtual Conference, Jul-19-2021 through Jul-22-2021

2021-07-16 13:36:00

Amgen Inc. Presents at Cambridge Health Institute PEGS Virtual Conference, Jul-19-2021 through Jul-22-2021. Presentation Date & Speakers: Jul-19-2021, Raymond J. Deshaies, Senior Vice President of Global Research. Jul-21-2021, Xiaoyan Guan, Senior Scientist, Process Development.

Neutral

Cambridge Healthtech Institute, Inc., Cambridge Health Institute PEGS Virtual Conference, Jul 19, 2021 through Jul 22, 2021

2021-07-16 12:52:00

Cambridge Healthtech Institute, Inc., Cambridge Health Institute PEGS Virtual Conference, Jul 19, 2021 through Jul 22, 2021.

Neutral

Amgen Inc. Presents at CannPack West 2021, Aug-10-2021

2021-07-15 14:57:00

Amgen Inc. Presents at CannPack West 2021, Aug-10-2021 . Speakers: SUSAN NEADLE, Executive Director & Head of Combination Products, Devices, Diagnostics and Digital Health Regulatory Affairs.

Neutral

Amgen Inc. Presents at 2021 FDA/PDA Joint Regulatory Conference, Sep-27-2021

2021-07-15 14:25:00

Amgen Inc. Presents at 2021 FDA/PDA Joint Regulatory Conference, Sep-27-2021 . Speakers: Kathy A. Demarest, Executive Director of Site Quality.

Neutral

Parenteral Drug Association, U.S. Food and Drug Administration, 2021 FDA/PDA Joint Regulatory Conference, Sep 27, 2021 through Sep 29, 2021

2021-07-15 13:17:00

Parenteral Drug Association, U.S. Food and Drug Administration, 2021 FDA/PDA Joint Regulatory Conference, Sep 27, 2021 through Sep 29, 2021.

Neutral

Informa Markets Limited, CannPack West 2021, Aug 10, 2021 through Aug 12, 2021

2021-07-15 13:02:00

Informa Markets Limited, CannPack West 2021, Aug 10, 2021 through Aug 12, 2021.

Positive

Amgen Announces U.S. Food and Drug Administration Accepts Biologics License Application

2021-07-08 06:00:00

Amgen announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Tezepelumab is being developed by Amgen in collaboration with AstraZeneca. The FDA grants Priority Review to applications for medicines that offer significant advantages over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.1 The Prescription Drug User Fee Act goal date for a decision by the FDA is during the first quarter of 2022. Despite recent advances in severe asthma, many patients may not qualify for or respond well to current biologic medicines.2-5 Patients with severe, uncontrolled asthma experience frequent exacerbations, significant limitations on lung function and a reduced quality of life. The BLA was based on results from the PATHFINDER clinical trial program, including results from the pivotal NAVIGATOR Phase 3 trial in which tezepelumab demonstrated superiority across every primary and key secondary endpoint compared to placebo in a broad population of patients with uncontrolled asthma while receiving treatment with medium- or high-dose inhaled corticosteroids (ICS) plus at least one additional controllermedication with or without oral corticosteroids (OCS).8 There were no clinically meaningful differences in safety results between the tezepelumab and placebo groups in the NAVIGATOR trial. The most frequently reported adverse events with tezepelumab were nasopharyngitis, upper respiratory tract infection and headache.

Neutral

Amgen Inc., Q2 2021 Earnings Call, Aug 03, 2021

2021-06-30 13:01:00

Amgen Inc., Q2 2021 Earnings Call, Aug 03, 2021

Neutral

Amgen Inc. Presents at The European Pharma Law Academy, Sep-06-2021 through Sep-10-2021

2021-06-29 16:36:00

Amgen Inc. Presents at The European Pharma Law Academy, Sep-06-2021 through Sep-10-2021. Presentation Date & Speakers: Sep-06-2021, Robert Jenny, Senior Counsel and Director. Sep-07-2021, Robert Jenny, Senior Counsel and Director.

Fundamental Summary

Amgen released impressive Q1 results on 2022-04-28. Their positive income, growth, and value factors indicate that it is likely to continue to produce impressive results for the foreseeable future, as well. We expect that this positive performance will continue in the coming months, and anticipate that Amgen will maintain good momentum even in a challenging environment. As such, Amgen received an overall score of 77 and a HOLD recommendation.

Amgen reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 6,238 million compared to USD 5,901 million a year ago. Net income was USD 1,476 million compared to USD 1,646 million a year ago. Basic earnings per share from continuing operations was USD 2.69 compared to USD 2.85 a year ago. Diluted earnings per share from continuing operations was USD 2.68 compared to USD 2.83 a year ago.

Business Description

Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Sector Overview

Amgen is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Amgen's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 59,196.0 -3.2% 68
Liabilities 58,280.0 7.0% 72
Price to Book 140.0 646.7% 62
Cash & Equivalents 6,528.0 -18.3% 53
Equity 916.0 -86.3% 86
EBITDA 13,091.0 2.4% 75
Total Revenues 26,316.0 1.3% 74
Parameter Value Change Score
Return on Equity 111.7 52.6% 64
Net Cashflow 416.0 -75.9% 80
Capital Expenditure -904.0 -2.7% 67
Asset Turnover 0.4 3.3% 74
Free Cashflow 15.0 1.7% 74

* All values are TTM

The below chart reflects Amgen's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Amgen's peer average final assessment score stands on 76.0, Amgen's score is 77.

  •  AMGN
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 0 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 1 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 2 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 3 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 4 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 5 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 6 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 7 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 8 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 9 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 10 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 11 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 12 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 13 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 14 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 15 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 16 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 17 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 18 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 19 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 21 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 22 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 23 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 25 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Amgen's stock is now priced above its 5-day and 200-day, but below its 50-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a positive setup in the near and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Amgen's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 52.

Bearish 52
Close Price 243.51
52W Low 198.88
52W High 256.74
5D MA 243.39
50D MA 244.2
200D MA 227.35
MACD -0.84
RSI 45.14
STOCH 86.66

Balance Sheet Analysis

Amgen appears likely to maintain its strong balance sheet metrics and momentum going forward. Amgen did a great job related to equity this period, which stood at 916.0, representing a -86.3% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. These metrics are all the more impressive relative to their peers and should support an upswing in their stock price. The company's equity movement component, therefore, received a grade of 86. Also, In terms of liabilities, Amgen published good numbers. Their reported liabilities were 58280.0, representing a 7.0% change from the previous report. These liabilities changes appear balanced compared to their peers and project the message that management is capable and focused on balancing asset growth, resource allocation, and growing liabilities. Therefore, we rated their liabilities movement with a score of 72. That said, one metric, Cash & Equivalents, stood out as particularly concerning. Amgen did a poor job related to managing cash and cash equivalents this period, which stood at 6528.0, representing a -18.3% change from the previous filing. The company's cash and cash equivalents metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Consequently, their cash and cash equivalents movement received a grade of 53. Similarly, because their management is doing an excellent job managing these critical metrics, the balance sheet was given a score of 69.

Parameter Value Change Score
Assets 59,196.0 -3.2% 68
Liabilities 58,280.0 7.0% 72
Price to Book 140.0 646.7% 62
Cash & Equivalents 6,528.0 -18.3% 53
Equity 916.0 -86.3% 86
* All values are TTM

The below chart describes Amgen's performance as reflected on its balance sheet with respect to its peers. While Amgen received a balance sheet score of 69, the average of its peers stands on 75.0.

  •  AMGN
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 0 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 1 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 2 1
BioNTech SE 34.0B 75 69 64 97 73 75 3 1
Seagen Inc. 32.9B 59 68 55 43 66 61 4 1
Biogen Inc. 29.7B 57 72 92 50 76 76 5 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 6 1
Incyte Corporation 16.8B 71 72 95 82 79 83 7 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 8 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 9 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 10 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 11 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 12 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 13 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 14 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 15 1
Alkermes plc 5.0B 63 66 46 54 71 62 16 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 17 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 18 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 19 1
Natera, Inc. 3.6B 73 65 43 95 42 54 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 21 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 22 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 23 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 25 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Amgen seems to be balancing strong EBITDA and Revenue Efficiency along with an overall impressive positive income statement. Amgen's management was effective in improving its EBIDTA, which now sits at 13091.0 and represents a 2.4% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its EBITDA component earned a score of 75. Also, Amgen reported highly encouraging numbers for its revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 74. On the other hand, Return Factors, jumped out as looking problematic. Return factors metrics and ratios were disappointing in this report. Amgen reported a return on equity (ROE) ratio of 111.7, representing a change of 52.6% from the last report.change of 52.6% from the previous period. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. These numbers show that management has been unsuccessful in fostering appropriate growth related to return on assets and return on equity momentum relative to their peers. Consequently, their return factors received a grade of 64. Consequently, the companie's income statement earned a rank of 78.

Parameter Value Change Score
EBITDA 13,091.0 2.4% 75
Total Revenues 26,316.0 1.3% 74
Return on Equity 111.7 52.6% 64
* All values are TTM

The below chart describes Amgen's performance as reflected on its income statement with respect to its peers. While Amgen received a income statement score of 78 , the average of its peers stands on 72.0.

  •  AMGN
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Gilead Sciences, Inc. 78.0B 78 71 52 73 0 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 1 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 2 1
BioNTech SE 34.0B 41 89 75 79 3 1
Seagen Inc. 32.9B 54 65 70 62 4 1
Biogen Inc. 29.7B 90 57 73 70 5 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 6 1
Incyte Corporation 16.8B 59 77 60 73 7 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 8 1
United Therapeutics Corporation 10.6B 57 91 54 82 9 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 10 1
Exelixis, Inc. 6.7B 54 91 54 81 11 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 12 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 13 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 14 1
Ascendis Pharma A/S 5.2B 38 68 46 54 15 1
Alkermes plc 5.0B 69 55 81 62 16 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 17 1
Novavax, Inc. 4.0B 41 89 54 75 18 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 19 1
Natera, Inc. 3.6B 52 51 78 52 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 21 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 22 1
Insmed Incorporated 2.4B 51 58 73 57 23 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 25 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two main cash flow metrics, Net Cash Flow and Asset Turnover, are driving the positive outlook for Amgen's financial strength. Amgen's management was effective in improving their net cash flow, which now sits at 416.0 and represents a -75.9% change from the previous report. Their net cash flow metrics are especially remarkable relative to their peers. Consequently, their net cash flow movement received a grade of 80. Also, Amgen's published asset turnover numbers were encouraging and reflected management's balanced change strategy. Amgen recorded asset turnover of 0.4, which represents a 3.3% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Its asset turnover metrics are especially remarkable relative to their peers. We believe the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its asset turnover movement earned a score of 74. That said, one metric, Capital Expenditure, stood out as particularly concerning. Amgen's published capital expenditures (CapEx) numbers were discouraging and reflected management's unbalanced growth strategy. Amgen recorded CapEx of -904.0, which represents a -2.7% change from the previous report. They appears to be headed in the wrong direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their CapEx movement received a grade of 67. Its cash flow received an overall score of 81.

Parameter Value Change Score
Net Cashflow 416.0 -75.9% 80
Capital Expenditure -904.0 -2.7% 67
Asset Turnover 0.4 3.3% 74
Free Cashflow 15.0 1.7% 74
* All values are TTM

The below chart describes Amgen's performance as reflected on its cash flow with respect to its peers. While Amgen received a cash flow score of 81, the average of its peers stands on 70.0.

  •  AMGN
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 0 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 1 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 2 1
BioNTech SE 34.0B 73 97 50 52 72 3 1
Seagen Inc. 32.9B 53 53 50 87 58 4 1
Biogen Inc. 29.7B 58 54 90 73 66 5 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 6 1
Incyte Corporation 16.8B 78 79 92 74 84 7 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 8 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 9 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 10 1
Exelixis, Inc. 6.7B 79 90 89 83 87 11 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 12 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 13 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 14 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 15 1
Alkermes plc 5.0B 89 95 76 80 92 16 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 17 1
Novavax, Inc. 4.0B 62 38 63 54 60 18 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 19 1
Natera, Inc. 3.6B 52 54 56 84 58 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 21 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 22 1
Insmed Incorporated 2.4B 79 80 61 89 82 23 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 25 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.